



सत्यमेव जयते



क.रा.बी.नि.
ESIC

कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

**DG-ESIC CENTRAL RATE CONTRACT NO. – 165
FOR SUPPLY OF DRUGS**

(VALID FROM 11th DECEMBER, 2025 to 10th DECEMBER, 2027)

DRUGS FOR GASTRO INTESTINAL SYSTEM

DRUGS FOR MUSCULO-SKELETAL DISORDERS & TISSUE INFLAMMATION

DRUGS FOR EYE & ENT

STRICTLY FOR OFFICIAL USE

मुख्यालय/HEADQUARTERS'

कमरा नंबर 312 और 321, तीसरी मंजिल, पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002

Room No. 312 & 321, 3rd Floor, Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002

www.esic.gov.in, ☎ 011-23604773, ✉ dmc-rc@esic.gov.in

Singh
12/12/25

2025-2027

1 | Page



क.रा.बी.नि.
ESIC

S.No.	Contents	Page No.
1.	Forwarding letter along with terms & conditions for operation of Rate Contract No. 165	1-12
2.	List of Approved Pharmaceutical firms of Rate Contract No. 165	13-19
3.	Indexing of approved Items	20-24
4.	Rate Schedule of Rate Contract No. 165	25-45

क.रा.बी.नि.
ESIC

STRICTLY FOR OFFICIAL USE ONLY



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS'
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002 www.esic.gov.in,
☎011-23604773, ✉ dmc-rc@esic.gov.in

No. U-25/12/165 to 169/2024-Medical.V (E-754406)/165 (RC-165)

Dated: 12.12.2025

From:

The Director General,
E.S.I. Corporation,
Panchdeep Bhawan,
C.I.G Road,
NEW DELHI - 110 002.

To

Director (Medical) Delhi/Noida
Dean-PGIMSR's/ All ESIC Medical Colleges & Hospitals/Dental Colleges
Medical Superintendent – All ESIC & ESIS Hospitals,
Director, ESI Scheme – All States & UTs.

Sub: **PROCUREMENT OF DRUGS UNDER ESIC CENTRAL RATE CONTRACT NO. 165 EFFECTIVE FROM 11.12.2025 TO 10.12.2027.**

Sir / Madam,

Please find enclosed a copy of the DG-ESIC Centralized Rate Contract duly adhering to Public Procurement (Preference to Make in India) Order, 2017 (as amended and revised till date) and related notifications from the relevant Nodal Ministry/ Department, finalized for supply of Drugs under the ESI Scheme in the country.

Validity of this Rate Contract is for a period of two years i.e. w.e.f. 11.12.2025 TO 10.12.2027.

Further, the following terms & conditions are issued to govern operation of the Rate Contract:

1. Immediately on receipt of this communication, the Chief Direct Demanding Officers- Medical Superintendent/Dean/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO shall intimate the names and complete address of the officers who have been designated as Direct Demanding Officer for the purpose of operation of this Rate Contract on his/her behalf, to all the Rate Contract holders. The Rate Contract holders would entertain the supply orders & related correspondences from the officers working as DDOs only after the receipt of such communication from the Chief DDOs.

2. Supply orders will be placed by Medical Superintendents/Deans/Director, Insurance Medical Services of various States, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director General, ESI Corporation in all matters connected with the execution of supplies and / or wherever specifically provided in the terms & conditions of the Rate Contract. The Chief Direct Demanding Officer can also designate any of his subordinate officer as Direct Demanding Officer (DDO) to operate this Rate Contract.
3. All the supply orders shall be signed only by the officers who have been duly authorized and included in the list of DDOs. **DDOs will send scanned copy of the Purchase Order mandatorily through email followed by speed post directly to the Approved Pharmaceutical Firm. The due date of delivery will be counted from the date of issuance of purchase order via email. It shall be the responsibility of DDOs to monitor the activity of placing purchase order via email/online module.**
4. The Chief DDOs may bring to the notice of the undersigned the discrepancies (especially in rate, packing, composition of the drug) if any observed by them.
5. The Chief DDOs shall monitor the performance of the Rate Contract holding firms in regard to their execution of supply orders in time. He shall send a consolidated quarterly non-supply report along with the comments and details as under: -

PROFORMA FOR NON-SUPPLY REPORT

R.C. No.	Item No. & Name of Drug	Name of firm	S.O. No. with Date	Preference (L1/L2/L3)	Qty. not supplied	Risk Purchase/ penalty levied	Payment if pending	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.

6. The applicability of GST may affect to some extent the rates finally approved under this Rate Contract and in such cases, orders may be placed to the firm at the lowest rates. While taking this step, the benefit of concession in rate of GST available under GST Act or the rules framed there under will be taken into account.
7. It will be ensured before placing order by the Direct Demanding Officer that necessary funds are available and **payment of bills should be arranged expeditiously within 4-6 weeks time of the execution of the orders by the Rate Contract Holder and there should not be unnecessary delay in the payment of their bills.**
8. Supply orders/Purchase order(s) will be placed from time to time during the currency of the contract in which the exact quantities required on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers.



9. No guarantee can be given as to the minimum quantity which will be drawn against this contract but the approved Pharmaceutical firm will supply quantity as may be ordered by the Direct Demanding Officers during the currency of the contract.
10. The approved Pharmaceutical firm will supply the items immediately on demand or latest within six weeks of placing of supply order throughout the period of contract.
11. Supply orders/Purchase orders against the contract will be accepted as long as these reach the approved Pharmaceutical firm on or before last date of the currency of the contract. Supply orders received during the closing days should be complied within due course, in accordance with the contract if even though in some cases owing to contract having expired, supplies are to be complied with even after the expiry of the last date of the contract.
12. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm to supply the item as per the specifications of the relevant rate contract.

SUPPLIES

13. The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance, Octroi etc, if any, will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the contractor of any loss or damage to the stores, that may have occurred during the transit.
14. During transit approved Pharmaceutical firm should maintain the recommended temperature of the drug (wherever indicated), otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled. It will be counted as a non-supply.
15. The prices approved are F.O.R. Destination per unit and are exclusive of GST except where indicated but inclusive of all charges for packing and forwarding.
16. In all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the public/open market.
17. **The approved** Pharmaceutical firm will have to supply drugs directly in the quantity ordered, to ESIC or ESIS Institutions. The approved Pharmaceutical firm shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons. In case, at any stage of the contract, it is found that the approved Pharmaceutical firm has appointed the distributors/dealers/third party agent for making supply or receiving of supply order against the contract, ESI Corporation will initiate the following actions against the approved Pharmaceutical firm(s):



- a. 100% forfeiture of Performance Security from the valid current all DG-ESIC Rate Contract(s).
- b. Blacklisting for participation in the future tender enquiries for all ESI Institutions for a period of two years prospectively.

18. Marking/Labelling:

Each packing shall be printed with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under. Packing & packaging of each drug must comply with the procedure provided under the Legal Metrology Act, 2009 and rules made there under.

19. Packing:

- a) **It should be ensured that all labels of cartons, ampoules, vials, bottles, jars, tubes, tins, containers etc., have "For ESI supply, Not to be sold" imprinted/rubber stamping with indelible ink clearly. Any consignment without such stamping will not be considered valid and will be rejected.**
- b) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be accepted under any circumstances.
- c) Supplies to be made in proper boxes.
- d) Liquid orals to be supplied only in glass/ plastic bottles conforming to Drugs & Cosmetics Act and rules made there under.
- e) Large volume parenterals to be supplied only in plastic bottles / polypacks conforming to Drugs & Cosmetics Act and rules made there under.
- f) It should be ensured that only **first use packaging material of uniform size including Bottles and vials** should be used for making supplies on the basis of ESI Rate Contract.
- g) All primary packing containers should be strictly conforming to the specifications described/ mentioned in the relevant pharmacopoeia.
- h) Packing should be able to prevent damage or deterioration during transit.
- i) All containers i.e. bottle, tins, cartons, tubes etc., are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents. MRP should not be written on any labels otherwise it will be disqualified.
- j) All DGESIC approved pharmaceutical firm will make supply bearing Quick response code on its label at each level packaging that store data or information readable with software application to facilitate tracking and tracing as per Gazette Notification and CDSCO guidelines time to time (Where ever Applicable).

20. Life Period :

I:

- a) For Drugs having shelf life of Two years or less: As on the date of delivery, Drugs should not be older than one fourth (1/4) of its shelf life from the date of manufacture.
- b) For Drugs having shelf life more than Two years: As on the date of delivery, Drugs should not be older than one sixth (1/6) of its shelf life from the date of manufacture.
- c) Imported Drugs: As on the date of delivery, Drugs should have a minimum 50% of valid shelf life from the date of manufacture.

II.

Notwithstanding the above, DDOs/Authorized nominated officer by DDO may relax this criteria in case of exigencies with reasons duly recorded and shall be responsible for use of that stores within its given shelf life, with a suitable undertaking from the supplier, the terms of which shall be decided by the consignee as per the requirement of the stores and usage pattern. The Consignee should ensure that there should not be any financial loss to the Corporation.

21. Pharmacopoeia Specifications:

Pharmacopoeia Specification IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the formulation supplied as per the provisions of Drug and Cosmetics Act.

22. The Stores accepted should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder as amended upto date and Drug Price Control Order.
23. It should be ensured that ISI Code No. is indicated on the packing and at the time of supplies, it must be ensured that the items supplied has ISI Mark as well as Code No., as is the statutory requirement of the Bureau of Indian Standards (Where ever Applicable).

24. Testing of Drugs – Quality Control

- a. Approved Rate Contract Holder should mandatorily submit a Test Report for that particular batch of medicines tested by the Government/Government approved Laboratories along with each supply, failing which supply received will be liable for rejection at the inspection stage and penalty of late supply will be levied as per provisions.
- b. Regular testing of 10% of supplies of drugs received in a month will be under taken by ESI from Govt./Govt. approved laboratories. Additional quality testing may also be undertaken by ESI Institutions at any time during the shelf life or whenever any defect is noticed.



- c. Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the approved Pharmaceutical firm/ firms at regular interval to maintain and ensure the quality of drugs.
- d. Details of the items found not of standard quality should be brought to the notice of the undersigned along with the test reports immediately. All such test reports should necessarily come through Chief D.D.Os only. A copy of the test report should be sent immediately to the firm, the concerned Drug controllers, and respective Central Drug Control authorities for necessary action.
- e. The report of the Govt./Govt. approved laboratory shall be accepted by the approved Pharmaceutical firm. In case the same is disputed by the approved Pharmaceutical firm the report of the Appellate Laboratory only will be accepted as final. However, the same should be submitted **within three months**, from the date of communication of the disputed test report to the approved Pharmaceutical firm. For this, the approved Pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure, from the Appellate Laboratory **at their own cost**. In case no response is received from the approved Pharmaceutical firm within the stipulated period, action as deemed fit as per terms & conditions of the Rate Contract will be initiated.
- f. For imported items: - The approved Pharmaceutical firm must submit the In-house test report of Principal manufacturer with each and every batch of supply.
- g. If any drug/s supplied against this Rate Contract are found to be "Not of Standard Quality" on inspection by Competent Authority, the approved Pharmaceutical firm will be liable to replace the entire quantity within 15 days otherwise risk purchase will be charged from the approved Pharmaceutical firm/s.
- h. If the product is found to be "Not of Standard Quality", the cost of testing will be recovered from the approved Pharmaceutical firms and further action will be taken as per clause no. 25 mentioned below:
25. The classification of defects into different categories is as per the guidelines issued by the Drugs Controller General (India), Central Drugs Standard Control Organization (CDSCO) & action will be taken by ESIC for each category of defects, described as below: -

A. CATEGORY 'A' DEFECT (Spurious / Adulterated Drugs)-

If any item / Batch of the item declared Not of Standard quality (NSQ) under Category A .

- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Recoveries to be initiated by the DDO's wherever payment had been made already.
- **100% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for all the quoted drugs.

- Debarring of the Rate Contract holder /approved Pharmaceutical firm from current and all future DGESIC Rate Contract for participation in tender enquiry of all ESIC institutions prospectively for a period of two years.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drug.

B. CATEGORY 'B' DEFECT (Grossly Substandard Drugs):

1. If single item/ Batch of item is declared NSQ under Category B:

- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **20% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for that drug as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item.
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

2.

a) If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category B

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **50% (20% + 30%) Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2nd NSQ) as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- **Any subsequent (3rd onwards) NSQ reported** of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current and all future DGESIC Rate Contracts for a period of two years for participation in all ESI Institutions prospectively along with forfeiture of **100% performance security for all NSQ declared items.**



- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.
- b) If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category B within a year**
 - Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
 - **100% Forfeiture of Performance Security from the respective DGESIC Rate Contract for this item (2nd NSQ) as per clause 13(III) of TE.**
 - Debarring of Rate Contract Holder/approved Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for the item for a period of two years for participation in all ESI Institution prospectively.
 - Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

C. CATEGORY ' C ' DEFECT (Minor Defects)

1.If single item/ Batch of item is declared NSQ under Category C

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

2.

a)If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category-C.

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- Warning to be issued to the firm for the NSQ item.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

b) If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category C within a year.



- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **10% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2nd NSQ) as per clause 13(III) of TE.
- **Any subsequent (2nd NSQ onwards)** NSQ reported of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current DGESIC Rate Contracts.
- Warning to be issued to the firm for the NSQ item
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

26. **Delivery Period – Risk Purchase**

- a. Delivery period will be of six weeks from the date of **issuance of purchase order via email** and the approved Pharmaceutical firm shall execute the order within stipulated time.
- b. If the approved Pharmaceutical firm fails to execute the supply order within the stipulated period of six weeks, a penalty of two (2) percent of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 10% of the total value of the order/orders. An approved Pharmaceutical firm can seek extension of the delivery period with the prior consent of the Direct Demanding Officers, if it is not in a position to execute the order in time. Such extension is permissible for a maximum period of 5 weeks only but penalty will be levied. The extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned DDO.
- c. In case of failure to supply, the Corporation reserves the right to purchase the stocks from other sources as risk purchase, i.e. purchase from any other approved Pharmaceutical firm or firms, in the rate contract or from outside the contract at the discretion of the Direct Demanding Officer concerned at a competitive rate or from local chemist. All DDOs of ESIC & ESIS Institutions shall record each instance of Non-Supply of respective approved Pharmaceutical Firm and a consolidated quarterly non-supply report to be submitted at ESIC HQRS.

Extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned Officer.

- d. i) If the items/ drugs are not supplied by the schedule date (as indicated above or by the extended date) full or in part, the order in respect of the quantity not supplied is liable to be cancelled at the risk and expense of approved Pharmaceutical firm. **The**



extra expenditure involved in procuring supplies from elsewhere i.e. L2 firm/other running Govt. Contract/ Local Purchase etc. will be recoverable from the approved Non-supplying Pharmaceutical firm, in full by Direct Demanding Officers.

ii) The recoveries thus due will be deducted from any sum payable by the Direct Demanding Officer or which at any time thereafter may become payable under this contract or any other contract placed with bidder by the Direct Demanding Officers. He will be deemed to be exercising the powers of Director General, ESI Corporation in case any such contingency arises. Apart from risk purchase action, the bidder's Performance security deposit may be forfeited and shall invite other penal action like debarring from participating in ESI Corporation Rate Contract present and future for a period of not less than two years.

- e. If the approved Pharmaceutical firm fails to execute the supply order three times at any location of ESIC & ESIS in any part of the country during the period of rate contract, it shall be debarred for the next two years with effect from the last failure and forfeiting of Performance Security for that drug.

27. Payment

Payment for the supply will be made within 4 to 6 weeks (after receipt and acceptance of the drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills are submitted. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm/bidder to supply the items as per the specifications of the relevant rate contract. No claim for the payment from contractor shall be entertained after the lapse of three years of arising of the claim.

28. Any dues or payments that have arisen to the Corporation from the approved Pharmaceutical firm for which no specific time limit has been laid down in the terms and conditions shall be payable by the approved Pharmaceutical firm within such time limit as may be prescribed in the letters/orders addressed to the approved Pharmaceutical firms.
29. Any payments that have been demanded as per the provisions of above-mentioned clause or under any other clause shall be payable within the time laid down. On failure to do so:
- The approved Pharmaceutical firm shall be liable to be debarred for supplying items/ drugs etc. to the Corporation for a period not exceeding two years.
 - The Corporation reserves its right to take appropriate legal action against the defaulting firms as may be legally advised, including claim for compensation and damages for the period of delay and / or simple interest 10% per annum for each day of default.
30. Rate Schedule along with list of item-wise finalized rates, along with name of the approved firms is enclosed: -



(a) Items where rates of more than one firm have been approved, order should be placed to the firm at First Preference and whose rates are the lowest. In case of non-supply by such firm, order shall be placed to the firm with the next higher approved rate invoking risk purchase.

(b) In case of items, where two approved Pharmaceutical Firms exist at L-1(1st Preference), it is mandatory for all Direct Demanding Officers (DDOs) to place Supply Orders in the ratio of 50% of the order quantity to each L-1 approved Pharmaceutical firm on each instance of placing of supply order. Same principal applies to L2 Firm(in case order is required to be placed with L2).

(c) For item No. 1675 & 2029 in RC-165, L-2 firms are Class-I Local Suppliers & have agreed to match the price of L-1 bidder. Therefore 50% of the order quantity to each L-1 approved Pharmaceutical firm to be placed on each instance of placing of supply order.

31. No other document should be entertained for giving any cognizance for placing the supply orders.
32. The validity of the contract of approved Pharmaceutical firm holding Patent right of approved drug/s in the currency of Rate Contract shall be for two years or till date of expiry of patent whichever is earlier. It is the sole responsibility of the patent holding firm to mandatorily inform ESIC Ten days before the expiry of the Patent of the approved drug/s in Rate Contract, failing which the participating firm shall be blacklisted in the participating and prospective RCs for a period of two years along with forfeiture of EMD/ Performance security (as the case may be) as per Terms & Conditions of the Tender Enquiries.
33. The Letter of Award issued to the firms by this office cannot be used for placing orders.
34. Standing Committee on Government e-Market (SCoGeM), Ministry of Labour & Employment has granted exemption to publish and operate DG-ESIC Rate Contract for the Drugs other than drugs reserved for CPSUs.
35. Force Majeure:
If at any time during the applicability of Contract the bidder fails to discharge its Obligation due to force majeure (natural disaster or act of God etc.) he will promptly notify the Director General or its representative about the happening of such an event. The Director General or its representative is solely entitled to terminate/ determine the order/contract in respect of such performance of the bidder(s) obligations if he so desires. The obligations under the contract on behalf of bidder for the contract shall be resumed as soon as practicable after the event has come to an end or ceased to exist.
36. It shall be the sole responsibility of Medical Superintendents/Deans/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO/ Head of Institutions of respective State to maintain



an optimum Inventory level with strict control as per ABC-VED matrix and ensure the drug formulary of the respective institution is followed in right earnest to provide medical services to ESI Beneficiaries.

37. All Deans/MSs/DIMS/Head of ESIC & ESIS Institutions are requested to keep a vigilant check on procurement of drugs (strictly monitor Re-Order Level, Buffer Stock, Lead Time etc.) in order to avoid obsolescence/expiry/excessive procurement of drugs resulting in infructuous expenditure.

This issue with the approval of Competent Authority.

Yours faithfully,

Encl.: As above.



(Dr. Sanjiv Kochhar)
Dy. Medical Commissioner (RC)
For: DIRECTOR GENERAL

Copy to:

1. PPS/PS to Director General, ESIC for information.
2. PPS/PS to Finance Commissioner for information.
3. PPS/PS to Medical Commissioner (Procurement/ Medical Administration) for information.
4. Accounts Branch – V (Hqrs. Office)
5. All Chief Direct Demanding Officers (In-Charge) of ESIC and ESI Scheme of all States/UT's for information and with the request to circulate this letter along with enclosures among all DDOs under their control for necessary compliance. They are also requested to send the list of DDOs to the firms approved in the Rate Contract.
6. Website Content Manager for uploading on ESIC HQRS Website.
7. Guard File.

डॉ. संजीव कोचर / Dr. Sanjiv Kochhar
उप विक्ति आयुक्त / Deputy Medical Commissioner
क.रा.बी.नि.(मु.) / E.S.I.C. (H.Q.)
श्रम एवं रोजगार मंत्रालय, भारत सरकार
Ministry of Labour & Employment, Govt. of India
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली-02
Panchdeep Bhawan, C.I.G. Road, New Delhi-02



(Dr. Sanjiv Kochhar)
Dy. Medical Commissioner (RC)
For: DIRECTOR GENERAL

क.रा.बी.नि.
E S I C
डॉ. संजीव कोचर / Dr. Sanjiv Kochhar
उप विक्ति आयुक्त / Deputy Medical Commissioner
क.रा.बी.नि.(मु.) / E.S.I.C. (H.Q.)
श्रम एवं रोजगार मंत्रालय, भारत सरकार
Ministry of Labour & Employment, Govt. of India
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली-02
Panchdeep Bhawan, C.I.G. Road, New Delhi-02



List of Approved Pharmaceutical firms of Rate Contract No. 165

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
1.	165	Abbott Healthcare Pvt Ltd	3 Corporate Park, Sion Trombay Road, Chembur Mumbai 400071	(91-22) 38160527, (91-22) 38162401, 9833941108, institution.ahpl@abbott.com
2.	165	Abbott India Limited	3 Corporate Park, Sion Trombay Road, Chembur Mumbai 400071	(91-22) 38160527, (91-22) 38162401, 8076637791, institution.business@abbott.com
3.	165	Ajanta Pharma Ltd.	Ajanta House, 98/Govt. Industrial Estate, Charkop, Kandivali (West), Mumbai - 400 067	022 66061202/66061221, 022 66061200, 9821838599, dilip.bagdiya@ajantapharma.com
4.	165	ALPA LABORATORIES LTD	33/2, A.B. Road, Pigdamber 453 446, Indore (MP)	0731 4294567, 7415794617, tenders@alpalabs.in
5.	165	Bayer Pharmaceuticals Private Limited	Bayer House, Central Avenue, Hiranandani Estate, Thane (W) - 400607	022 2531 1234, 022 2545 5063, 9811694231, yogesh.prakash@bayer.com
6.	165	Biodeal Pharmaceuticals Ltd.	Vill. Saini Majra, Nalagarh Ropar Road Nalagarh, Himachal Pradesh 174101	0120-6025048, 0120-6025048, 7428744221, institution1@biodealpharma.com, Institution@biodealpharma.com
7.	165	Centaur Pharmaceuticals Pvt. Ltd.	Centaur House, A- Wing , Institutions Dept., Shanti Nagar, Vakola, Santacruz East Mumbai - 400055	022-66499270/274, 022-66499112, 98202244293, 9930593597, institutions@centaurlab.com, sameer@centaurlab.com
8.	165	Cipla Ltd.	Cipla House Peninsula Business Park, Ganpatrao Kadam Marg, lower Parel, Mumbai- 400 013	022 24826000, 022 24826120, +91 9820273567, +91 9506692389, Institution@Cipla.com, vishwas.ahuja@cipla.com, prashant.gupta1@cipla.com, praveen.kumar18@cipla.com
9.	165	DWD Pharmaceuticals Ltd.	Dalamal House, 4th floor, Nariman Point, Mumbai - 400 021	022 - 2853910 / 11, 022 - 22825753, 9969006343, corporate@dwdindia.com, factory@dwdindia.com
10.	165	Emcure Pharmaceuticals Limited	EMCURE PHARMACEUTICALS LIMITED, BUILDING A-202 & 202, GANGA OSIAN SQUARE , WAKAD , PUNE -411057, MAHARASHTRA INDIA	020-35070033, 020-35070033, 9830890292/7428714333, institution@emcure.com, Niladri.Das@emcure.com



List of Approved Pharmaceutical firms of Rate Contract No. 165

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
11.	165	GALPHA LABORATORIES LIMITED	E 221, Kanakia Zillion Junction of LBS Marg and CST Road, BKC Annexe, Kurla West, Mumbai - 400070	22 3040 0999, 22 3040 0900, 7718883168, kuldeep.malhotra@galpha.com, arindam@galpha.com, sanjay.pathak@galpha.com
12.	165	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Limited, Glenmark House, B.D.Sawant Marg, Chakala, Andheri East, Mumbai - 400099	022-40189999, 022-40189986, 9867027126, govt.tenders@glenmarkpharma.com
13.	165	HAB Pharmaceuticals & Research Ltd	A-301 PENINSULA BUSINESS PARK, GANPATRAO KADAM MARG LOWER PAREL MUMBAI 400013	022-66261409, 022-66261414, 9930212908, marketing@habpharma.in, institution@habpharma.in
14.	165	Heal (India) Laboratories Pvt. Ltd.	Heal (India) Laboratories Pvt. Ltd., 197/1 Periyapalayam Road, Manjankaranai Thiruvallur-(Dist) Chennai-601102.TAMILNADU	044-27629318, 9842883839, healindia ltd@gmail.com
15.	165	Healer's Lab	Avanbai Mansions, 3- Vidhan Sabha Marg, Lucknow-226001 U.P.	0522-2620365, 8795838376, institution.healerslab@gmail.com
16.	165	Hindustan Laboratories Limited	A-302, Victory Park, Chandavarkar Road, Borivali (West), Mumbai - 400092, Maharashtra	022-42460500, 42460526, 022-42460531, 7710055194, sales@hindlab.com, tender@hindlab.com, kunjaldedhia@hindlab.com
17.	165	Indoco Remedies Ltd.	Indoco Remedies Limited, Indoco House, 166, C.S.T. Road, Kali Santacruz (East), Mumbai - 400098.	022 - 6287 1000/ 6817 1250, 022 - 2652 0884, 9004046733, mshetty@indoco.com, kiran.borle@indoco.com
18.	165	Intas Pharmaceuticals Ltd.	Intas Pharmaceuticals Limited, Corporate House, Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad- 380054	079-39837000, -, 9810824433, abhishek_bajaj@intaspharma.com
19.	165	Ipcalaboratories Ltd.	Plot No. 48, Kandivali Industrial Estate, Kandivali West, Mumbai - 400067	022 - 6857 2895, 9870130466, sandesh.prabhu@ipca.com, dinesh.shukla@ipca.com
20.	165	J B Chemicals & Pharmaceuticals Ltd	Neelam Centre, B Wing, 4th floor, Hind Cycle Road, Worli, Mumbai:400030	22 2439 5200/ 2439 5500, 22 2431 5331 / 2431 5334, 9987863378, sajida.khan@jbpharma.com, anand.prasad@jbpharma.co



ए.एस.ई.सी.
E S I C

List of Approved Pharmaceutical firms of Rate Contract No. 165

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
				m
21.	165	LOGOS PHARMA	182/2, 3rd floor, Industrial area, Phase 1, Chandigarh-160002	0172-4822400, 6284300825, logos.tenders@gmail.com
22.	165	LUPIN LIMITED	3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai - 400055	(022) 66402969, (022) 66402969, 8879967909, manoj Singh4@lupin.com
23.	165	MAAN PHARMACEUTICALS LTD.	MAAN PHARMACEUTICALS LTD., PLOT NO.1, G.I.D.C PHASE-2, MODHERA ROAD, MEHSANA-384002	02762-224642, 02762 224610, 9825070124, info@maanpharma.com
24.	165	Macleods Pharmaceuticals Limited	Atlanta Arcade, Marol Church Road, Opposite Leela Hotel, Andheri (East), Mumbai - 400059	2266762672, 2229256599, 7304564056, tenders@macleodspharma.com
25.	165	MANKIND PHARMA LIMITED	M/s. Mankind Pharma Limited, 208, Okhla Industrial Estate, Phase-3, New Delhi-110020	011-46541400, 011-46541382, 9599911736, 9873661749, tender@mankindpharma.com, rajesh.kaul@mankindpharma.com, gaurav.saxena@mankindpharma.com
26.	165	MDC PHARMACEUTICALS LIMITED	PLOT NO. 46, INDUSTRIAL AREA, PHASE 2, CHANDIGARH 160002	9115516378, esisupplies@mdcpharmaceutical.com, legal@mdcpharmaceutical.com, singlamdc@gmail.com
27.	165	Med Manor Organics Pvt. Ltd.	16-11-477/45, Sri Krishna Nilyam, Dilsukh Nagar, Hyderabad - 500036	040-24053155 & 32934530, 040 - 24041284, 8898880276, yogendra.mishra@medmanor.in, ganesh.jayaraman@medmanor.in, esic@medmanor.in
28.	165	MEDOPHARM	No.25, Puliur 2nd Main Road, Trustpuram, Chennai - 600 024.	044-40149974, 044-40149999, 9080605427, institution@medopharm.com, gmc@medopharm.com
29.	165	MESMER PHARMACEUTICALS	Mesmer Pharmaceuticals, Vedha No 13, Mangala Nagar, 1st Main Road, Porur, Chennai-600116, Tamil Nadu.	044-22522618, 0, 9444903427, tenders.mesmer@iconlife.in, gvsmani.mesmer@iconlife.in
30.	165	MICRO LABS	No. 31, Race Course Road,	: +91-80-2237 0451-57 line,

8



List of Approved Pharmaceutical firms of Rate Contract No. 165

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
		LTD	Bangalore-560 001	: +91-80-2237 0463 , 9350808984 ; 9591211411, rakeshsharma_micro@yahoo .co.in
31.	165	MICRON PHARMACEUTICALS	Plot No. 2117, A-2, Phase III GIDC Vapi 396 195	0260 2405400/405/407/412, 0260 2405419, 9924170750, sales@micronpharma.in,cont actus@micronpharma.in,sale s@micronpharma.in
32.	165	MODI MUNDIPHARMA PVT LTD	1400, MODI TOWER, 98, NEHRU PLACE , NEW DELHI 110019	011 4250 4992, 4555, 011 4250 2645 1659, 9990432604, pmd@modimundipharma.co m,neeraj.dhalla@modimundi pharma.com,tenders@modi mundipharma.com
33.	165	Morepen Laboratories Limited	2nd Floor, Tower - C, DLF Cyber Park, Udyog Vihar - III, Sector - 20, Gurugram - 122016 (Haryana)	0124 - 4892000, 0124 - 4892000, 9891759817, yadvinder.singh@morepen.c om,institution@morepen.co m
34.	165	Nanz Medscience Pharma Pvt. Ltd.	Rampurghat, Paonta Sahib- 173025, District Sirmour, Himachal Pradesh	01704-227400, 0, 9805070502, admin@nanzpharma.com,na nz@nanzpharma.com,tender s@nanzpharma.com
35.	165	Overseas Health Care Private Limited	M/s. OVERSEAS HEALTHCARE PRIVATE LIMITED, 335KM Milestone, National Highway No.1, P.O. Box 25, Phillaur, District Jalandhar, Punjab State	01826-222886, 01826- 222885, 9872019733, info@overseashealthcare.co.i n,dmohcpl@gmail.com
36.	165	PRECISE CHEMIPHARMA PVT LTD	E311 AND E312, 3rd Floor, Eastern Business District, Neptune Mall, L.B.S. Marg, Bhandup (West), Mumbai, Maharashtra, 400078	91-22-67828600 to 99, 91- 22-67828600, 9819149266, tenders@precisegroup.co.in
37.	165	Primus Pharmaceuticals	Primus Pharmaceuticals, Sadhoura Road, Mouza Ogli Khari, Vill. Asgarpur Majra, Distt. Sirmour ,173030, H.P	9034004055 and 7056797055, tenders@primuspharmaceuti cal.com,marketing@primusp harmaceutical.com
38.	165	Raptakos, Brett & Company Limited	21A, Mittal Towers, 210,Nariman Point, Mumbai-400021	022-40856000, 022- 40856020, 9953804709, pankaj.vig@raptakos.net



List of Approved Pharmaceutical firms of Rate Contract No. 165

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
39.	165	RIVPRA FORMULATION PVT. LTD,	RIVPRA FORMULATION PVT. LTD. CORPORATE OFFICE: RADISSON BLU, KM TRADE TOWER, 11TH FLOOR, OFFICE NO: 1008, H-3, KAUSHAMBI, GHAZIABAD-201010 (U.P)	(0120-4277177), 0120-4277177, 9999811834, 8800394441, tender@rivpraformulation.com, info@rivpraformulation.com
40.	165	Roche Products (India) Pvt. Ltd	Roche Products (India) Pvt Ltd, 146-B, 166 A, Unit No. 7, 8, 9,8th Floor, R City Office, R City Mall Lal Bahadur Shastri Marg, Ghatkopar, Mumbai - 400 086	91 22 50457300, 91 22 50457301, 91 9967536395, india.institutionalbusiness@roche.com, prerana.yadav@roche.com
41.	165	SANOFI HEALTHCARE INDIA PRIVATE LIMITED	Sanofi house, CTS 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai - 400072. Maharashtra.	022 28032000, 022 28032939, 91 9312403063, institutionbusiness.shipl@sanofi.com, sangita.salunke@sanofi.com
42.	165	Signature Phytochemical Industries	Signature Phytochemical Industries, A-301 Peninsula Business Park Ganpatrao Kadam Marg Lower parel Mumbai 400013	022-66261400, 022-6624141, 8976716569, marketing@signaturepi.in
43.	165	Tablets (India) Limited	# 72, Marshalls Road, " Jhaver Centre" R A Building, 4th Floor, Egmore, Chennai, 600 008	044 - 4205 0000, 044 - 2858 9090, --, hd@tabletsindia.com
44.	165	Themis Medicare Limited	Themis Medicare Limited, 11/12, Udyog Nagar, S.V. Road, Goregaon(W), Mumbai-400104	91-22-67607080, 9022951026, instmgr@themismedicare.com
45.	165	Theon Pharmaceuticals Limited	Plot no. 400, Industrial Area, Phase-1, Panchkula-134113	0172-5210200, 0172-5033851, 7696000688, tender@theonpharma.com, psingh@theonpharma.com
46.	165	Tirupati Medicare Ltd.	Nahan Road, Paonta Sahib, Dist. Sirmour, Himachal Pradesh - 173025	9816700121, 9816700122, 7807880495, tina.issar@tirupatigroup.co.in
47.	165	Torrent Pharmaceuticals Ltd, Ahmedabad	Torrent Pharmaceuticals LTD, Torrent House, Off Ashram Road, Ahmedabad-380009	079 26599551, 079 26582100, 7069000550, 578, 509, 559, hemantameher@torrentpharma.com, vikrampatel@torrentpharma.com, jaydabhi@torrentpharma.com, bijendrakumarsharma@torrentian.com, ha



List of Approved Pharmaceutical firms of Rate Contract No. 165

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
				dmatkhatik@torrentpharma.com, ISDORDERS@TorrentPharma.com
48.	165	Troikaa Pharmaceuticals Limited	Troikaa House - 1, Satya Marg, Bodakdev, Ahmedabad - 380054	079 26856242, 079 26856246, 7227069020, tenderorder@troikaapharma.com, head_inst@troikaapharma.com
49.	165	ULTRA DRUGS PVT. LTD.	Corporate/Correspondence office: H.NO. 436, VILLAGE SAKETRI, DISTT. PANCHKULA-134109 (H.R.) Regd. Office: H.NO. 1201, SECTOR-22B CHANDIGARH-160022	0195-236918-20, 01795-236917, 78078 87915, manoj.tenders@ultradugs.co.in, director@ultradugs.co.in
50.	165	UNICURE INDIA LTD	C-21, 22 & 23, Sector-3, Noida-201301, distt. Gautam Budh Nagar (U.P.)	0120-4786713, 0120-4320184, 9810337912, unicare@unicureindia.com, mkumar712@gmail.com
51.	165	Virchow Biotech Pvt. Ltd.	Virchow Biotech Pvt. Ltd., 901, Dlh Park, S V Road, Goregaon West, Mumbai, Mumbai Suburban, Maharashtra, 400062	022-28795635/022-28735609, 022-28795699, 9833197751, shambhu.s@virchowpharma.com, kiran.saxena@virchowpharma.com
52.	165	Wallace Pharmaceuticals Pvt. Ltd.	Wallace Towers, 5th Floor, Navpada, Bahar Cinema, off WE Highway, Vile Parle(East), Mumbai-400057	022-68311133, 022-28390733, 9820360019 / 9811129701, pravinwani@wallacepharma.net, institution@wallacepharma.net, pravinwani@wallacepharma.net, institution@wallacepharma.net, ms379@hotmail.com
53.	165	Windlas Biotech Limited	705-706, Vatika Professional point, sector-66 golf course ext, road, Gurgaon-122001 Haryana	124-2821030, 124-2821060, 9555823672, institutionalhead@windlasbiotech.com
54.	165	Wings Biotech LLP	J-13, Udyog Nagar Industrial Area, Near Peeragarhi Metro Station, Delhi- 110041	011-45922222, 9871112877, manager.govtupply@wingsbiotech.com, institution.exe@wingsbiotech.com, wingstender.co@gmail.com
55.	165	ZIM	Saddoday Gyan (Ground Floor),	7122981960, 7118271470,



List of Approved Pharmaceutical firms of Rate Contract No. 165

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
		LABORATORIES LIMITED	Opp. NADT Nelson Square, Nagpur-440013 (MS)	9818678219, tendercell@zimlab.in,admin01@zimlab.in,marketing@zimlab.in
56.	165	Zuventus Healthcare Limited	Zuventus House, Plot Y2, CTS NO: 358/A2, Near Nahur Railway Station, Nahur (West), Mumbai-400078	022 35060000, 022 20812898, 9054797511, Rajiv.Kumar@zuventus.com, sheetal.khanvilkar@zuventus.com
57.	165	Zydus Lifesciences Limited	Zydus Lifesciences Limited 4th Floor, "B" Wing, 'Zydus Corporate Park', Scheme No. 63, Survey No. 536,Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S.G.Highway, Ahmedabad - 382 481, Gujarat, India.	+91-079-71800000, 91-079-48040000 , +91-079-71800192, +91-91-98723 14125, ZLL_Institution_Business@zyduslife.com,NishuS.Dubey@zyduslife.com

क.रा.बी.नि.
ESIC

भारतीय
ESIC**Index RC- 165**

S.No.	RC No.	Item No.	Item Name and Description
1	165	21	Furazolidone Susp-Each 5ml to contain: Furazolidone 25mg, 60ml Bottle
2	165	25	Metronidazole Susp-Each 5ml to contain: Metronidazole 200mg, 60ml Bottle
3	165	318	Naproxen Tab/Cap-Each Tab/Cap to contain: Naproxen 250mg.
4	165	387	Ondansetron Tab/Cap-Each Tab/Cap to contain: Ondansetron 4mg.
5	165	415	Laxative Liquid - Each. 5 ml. to contain: Liquid Parafin 1.25ml., Milk of Magnesia 3.75ml., Sodium Picosulphate 3.33mg. Packing-110 to 200ml Bottle
6	165	417	Enzyme Drop- Each ml to contain: Alpha-Amylase (Bacterial 1:800) 20mg, Papain 10mg, Dill Oil 2mg, Anise Oil 2mg, Caraway Oil 2mg.,15ml Bottle
7	165	418	Enzyme Syp- Each 15ml to contain: Iodised Peptone 29 mg, Mag. Chl 20 mg, Mang. Sulph 4mg, Zn. Sulph. 6 mg, Sod. Metavandate 0.66 mg, Pyridoxine Hcl 0.75mg., Cyanocobalamin 0.5mcg, Nicotinamide 10mg, Alcohol 0.95 ml,300ml Bottle
8	165	478	Lactulose Syp-Each 15 ml to contain Lactulose 10gm., Packing-100ml to 150ml Bottle
9	165	482	Cipro + Dexta Eye Drop-Each Vial to contain: Ciprofloxacin 0.3%, Dexamethasone 0.1%, Benzalkonium Chloride 0.01%, Packing: 5ml to 10ml Vial
10	165	534	Pre & Probiotic Tab/ Cap-Each Tab/Cap to contain: Streptococcus faecalis 30 million, Clostridium butyricum 2 million, Bacillus mesentericus 1 million, Lactic acid bacillus sporogenes 50 million.
11	165	551	Clotrimazole + Lignocaine Ear Drop-Each Bottle to contain: Clotrimazole 1%, Lignocaine Hydrochloride 2%, 10ml Bottle
12	165	1029	Enzyme Tab/Cap-Each Tab/Cap to contain: Pepsin (1:3000) 12.5 mg., Fungal Diastase (1:2000) 18.75 mg
13	165	1096	Paracetamol Inj-Each ml to contain: Paracetamol 150mg, 2ml Amp
14	165	1098	Allopurinol Tab/Cap-Each Tab/Cap to contain: Allopurinol 100 mg.
15	165	1107	Serratiopeptidase Tablets, Each Tablet Contains: Serratiopeptidase 5mg (10,000 Units Of Serratiopeptidase)
16	165	1228	Acyclovir Eye Oint-Each Tube to contain: Acyclovir I.P.3%,5gm Tube
17	165	1240	Choline Salicylate Gel-Containing : Choline Salicylate 9.0% w/v, Benzalkonium Chloride 0.02%, 10ml Tube/Bottle
18	165	1413	Antacid Sachet- Each Sachet (0.67g) to contain: Water Soluble Azulene (Sodium Azulenesulfonate) JPC 2.01 mg, L-Glutamine JPC 663.3 Mg
19	165	1414	Prebiotic And Probiotic Sachet- Each Sachet (0.5gm) contains: Streptococcus faecalis T-110 30million Clostridium butyricum To-A 2million bacillus mesentericus To A 1 Million Lactic Acid





S.No.	RC No.	Item No.	Item Name and Description
			bacillus 50 million (Lactobacillus sporogenes)
20	165	1418	Thiocolchicoside Tab/Cap-Each Tab/Cap to contain: Thiocolchicoside 8mg
21	165	1432	Olopatadin Eye Drop-Each ml to contain: Olopatadin 1.0mg,5ml Vial
22	165	1496	Rabeprazole Sodium + Mosapride Citrate Tab/Cap- Each Tab/Cap to contain: Rabeprazole Sodium 20mg, Mosapride Citrate 15mg Sustained Release
23	165	1506	Bacillus Clausii Spores Susp - Each 5ml to contain: Bacillus clausii spores 2 Billion spores, susp.in 5ml distilled water,5ml pack
24	165	1507	Pre & Probiotic Tab/Cap- Each Tab/Cap.to contain: Streptococcus Faecalis T - 110 60 Million, Clostridium Butyricum TO-A 4 Million, Bacillus Mesentericus TO-A 2 Million, Lactic Acid Bacillus 100 Million. (Lactobacillus Sporogenes)
25	165	1543	Diacerein Tab/Cap- Each Tab/Cap to contain: Diacerein 50mg
26	165	1595	Levofloxacin Eye Drop-Containing: Levofloxacin soln. 0.5%,5ml Vial
27	165	1597	Moxifloxacin Eye Drop-Containing: Moxifloxacin soln. 0.5% w/v,5ml Vial
28	165	1599	Moxifloxacin Eye Oint- Each Tube to contain: Moxifloxacin 0.5%,5gm Tube
29	165	1655	Ilaprazole Tab/Cap-Each Plain/Gastro Resistant Tab/Cap to contain: Ilaprazole 10mg
30	165	1656	Laxative Powder - Each pouch to contain: Polyethylene Glycol 118 gm, Potassium Chloride 1.484 gm, Sodium Bicarbonate 3.37 gm, Sodium Chloride 2.93 gm, Sodium Sulphate 11.36 gm.,137.15 gm pouch
31	165	1657	Palonosetron Hydrochloride Inj -Each 1.5ml Contains: Palonosetron Hydrochloride equivalent to Palonosetron-0.075 mg water for Inj-q.s.,1.5ml vial
32	165	1658	Zinc Syp- Each 5ml to contain: Elemental Zinc 20mg, 100ml Bottle
33	165	1675	Lornoxicam SR Tab/Cap- Each SR Tab/Cap to contain: Lornoxicam 16 Mg
34	165	1742	Pre & Probiotic And Oral Rehydration Sachet- Each Pack-in-Pack Sachet WHO ORS Pack 4.10g contains: Sodium Chloride 0.52gm,Sodium Citrate 0.58gm,Potassium Chloride 0.3gm,Dextrose Anhydrous 2.7gm Pre & Probiotic Pack 0.5g contains: Streptococcus Faecalis T-110 7.5 Million,Clostridium Butyricum TO-A 0.5 Million,Bacillus Mesentericus TO-A 0.25 Million,Lactobacillus Sporogenes 20.0 Million.
35	165	1757	Etoricoxib Tab/Cap - Each Tab/Cap to contain: Etoricoxib 90 mg
36	165	1760	Hylan G-F20 Injection - Each contain: Hylan G-F20 ,6ml PFS. SYNVISIC ONE
37	165	1824	Lactulose Granules - Each 15gm of granules to contain : Lactulose BP 10 gm, Ispaghula Husk IP 3.50 gm, Pack of



ए. ए. सी. आई.
E S I C

S.No.	RC No.	Item No.	Item Name and Description
			90 Gram
38	165	1865	Tolperisone & Diclofenac Tab/Cap - Each film coated Tab/Cap to contain: Tolperisone Hydrochloride JP 150mg + Diclofenac Sodium IP 50mg, Excipients-q.s
39	165	1935	Fluticasone Nasal Spray - Each spray delivers Fluticasone Propionate IP 50mcg to contain: Fluticasone Propionate IP - 0.05% w/v, Benzalkonium Chloride IP - 0.01% w/v (as preservative) Phenyl Ethyl Alcohol Usp - 0.25% w/v (as preservative), 100 MD
40	165	2010	Pantaprazole 40mg + Domperidone 30 mg SR Tab - Each Tab/Cap to contain: Pantaprazole 40mg + Domperidone (SR) 30 mg
41	165	2012	Pre & Probiotic Dry Syrup - Each 5 ml to contains: Streptococcus faecalis T-110 30 million Clostridium butyricum TO-A 2 million Bacillus mesentericus TO-A 1 million Lactic acid bacillus (Lactobacillus sporogenes) 50 million Excipients q.s. 50ml Bottle
42	165	2029	Teriparatide 750 mcg Inj - Each 3ml cartridge to contain : Teriparatide 750 mcg
43	165	2059	Silymarin Tab/Cap- Each Film Coated Tab/Cap to contain: Metadoxine 500mg, Silymarin 140mg, L-Ornithine L-Aspartate 150mg, Pyridoxine Hydrochloride 3mg, Folic Acid 1.5mg
44	165	2082	Dexketoprofen + Paracetamol Tab/Cap- Each Tab/Cap to contain: Dexketoprofen 25mg, Paracetamol 325mg
45	165	2083	Aflibercept Injection 40 Mg / Ml Aflibercept (R-DNA Origin) Solution For Intravitreal Injection in Vial Each Pack to contain: 1 Vial and a 18 G Sterile Filter Needle 278 Microliters/Vial Each Single Dose Vial Provides A Usable Amount To Deliver A Single Dose Of 50 Microliters Containing 2mg Aflibercept
46	165	2187	Antacid Tab/Cap-Each Uncoated Tab/Cap to contain: Dried Aluminium Hydroxide I.P. 240 mg, Magnesium Hydroxide I.P. 100 mg, Activated Dimethicone I.P 25 mg, Light Magnesium Carbonate I.P 60 mg.
47	165	2192	Resistant Bacillus Clausii Tab/Cap: Each Tab/Cap Contains: 2 billion spores of polyantibiotic- Resistant Bacillus Clausii
48	165	2198	Each PFS to contain: Sodium Hyaluronate BP 80mg to 90mg (Cross Linked) Phosphate Buffer Saline Q.S., 1 PFS
49	165	2199	Baclofen Tab/Cap Each Tab/Cap to contain: Baclofen 10 mg
50	165	2250	Ondansetron Tab/Cap-Each Tab/Cap to contain: Ondansetron 8mg.
51	165	2255	Sodium Picosulphate Tab/Cap Each Tab/Cap to contain: Sodium Picosulphate 10 mg
52	165	2261	Aceclofenac & Tizanidine Tab/Cap-Each Tab/Cap to contain: Aceclofenac 100mg, Tizanidine 2mg
53	165	2276	Polyethylene Glycol & Propylene Glycol Eye Drop- Each Vial to contain: Polyethylene Glycol 400 0.4%, Propylene Glycol 0.3%, 10ml Vial
54	165	2279	Fluorometholone + Tobramycin Eye Drop-Each ml to contain:



भ.स.अ.सि.सि.
ESIC

S.No.	RC No.	Item No.	Item Name and Description
			Fluorometholone 0.1% w/v, Tobramycin 0.3% w/v ,5ml Vial
55	165	2283	Natamycin Eye Drop-Each ml to contain: Natamycin 5% w/v,5ml Vial
56	165	2291	Ofloxacin + Dexamethasone Eye Drop: Each ml to contain: Ofloxacin 0.3%, Dexamethasone 0.1%, 10mlVial
57	165	2297	Sodium Bicarbonate Tab/Cap- Each Tab/Cap to contain: Sodium Bicarbonate 500mg
58	165	2418	Metaxalone +Diclofenac Potassium Tab/Cap- Each Tab/Cap contain: Metaxalone 400mg +Diclofenac Potassium 50mg
59	165	2420	Fosapretant Dimeglumine inj- Each Vial/Amp to contain: Fosapretant Dimeglumine inj 150mg
60	165	2425	Loteprednol Etabonate Drop-Each Vial/Phial to contain: Loteprednol Etabonate 0.5%,5ml Vial
61	165	2426	Povidone Iodine Mouth Gargle-Each Bottle to contain: Povidone Iodine 2%, 100ml Bottle
62	165	2427	Triamcinolone Acetonide-Each Tube to contain: Triamcinolone Acetonide 0.1 % Paste, 5gm Tube
63	165	2533	Acotiamide Tab/Cap: Each SR/ER/Plain Tab/Cap to contain Acotiamide 300mg
64	165	2534	Acotiamide Tab/Cap: Each tab/cap to contain Acotiamide 100mg
65	165	2540	Chloramphenicol + Dexamethasone + Polymyxin B Eye Ointment: Each gram contain Chloramphenicol (10mg) + Dexamethasone (1mg) + Polymyxin B (10000 IU) ,5gm
66	165	2541	Cross linked Sodium Hyaluronate 88mg (22mg/ml) with Triamcinolone hexacetonide 18mg, 4ml Injection BOQ Unit: 1 vial/amp/PFS
67	165	2544	Policresulen+ Cinchocaine Ointment: Each gram contains : Policresulen 50 mg , Cinchocaine HCL BP 10mg Ointment base q.s,30gm Tube
68	165	2545	Esomeprazole+Levosulpiride:Each Tab/Cap to contain Esomeprazole 40mg+ Levosulpiride 75mg
69	165	2546	Etodolac 400mg Tab/Cap-Each Tab/Cap to contain: Etodolac 400mg
70	165	2547	Etoricoxib+Pregabalin Sustained Release Tablets/cap: Each Tab/Cap to contain Etoricoxib 60mg and Pregabalin 75mg Sustained Release
71	165	2548	Calcium Carbonate+Magnesium Hydroxide+Famotidine chewable tablet contains: Calcium Carbonate IP 800mg, Magnesium Hydroxide IP 165mg, Famotidine IP 10mg
72	165	2549	Faricimab injection contains: Faricimab 6mg/0.05ml injection
73	165	2550	Flupirtine Maleate Tab/Cap: Each SR/ER/Plain Tab/Cap to contain Flupirtine Maleate 400mg



ए. ए. सी. ई.
E S I C

S.No.	RC No.	Item No.	Item Name and Description
74	165	2553	Ketorolac+Moxifloxacin Eye Drop: composition Ketorolac 0.4% w/v +Moxifloxacin 0.5% w/v ,5ML
75	165	2554	Lactulose Enema:- Each ml contain Lactulose 200mg ,100ml
76	165	2555	Liquid Paraffin, 400ml
77	165	2556	Mefenamic Acid Syrup: Each 5ml contain Mefenamic acid 100 mg,60ml bottle
78	165	2558	Nalbuphine injection:Each ampoule contains Nalbuphine 10 mg ,1ml
79	165	2559	Nalbuphine injection:Each ampoule contains Nalbuphine 20 mg,1ml
80	165	2560	Netarsudil 0.02% Eye Drop: Each ml contain Netarsudil 0.2mg, 2.5ml to 5ml
81	165	2561	Pancreatin 25000 tab/cap: Each Tab/Cap to contain Pancreatin 300mg
82	165	2562	Paracetamol Injection (IM), 2 mlEach ml contains:Paracetamol IP-250 mg, Absolute Alcohol IP-0% v/v Water for Injections IP-q.s.
83	165	2563	Ripasudil 0.4% w/v Eye Drops:Each ml contain Ripasudil 4mg, pack of 5ml.
84	165	2564	Racecadotril sachet: Each Sachet contain Racecadotril 10mg, 1 g powder/sachet
85	165	2566	Sodium Hyaluronate 0.1% w/v Eye drops, 10ml pack
86	165	2568	Aceclofenac 100mg+Paracetamol 325mg+ Serratiopeptidase 15mg Tab/Cap
87	165	1015a	Prochlorperazine Tab/Cap- Each Tab/Cap to contain: Prochlorperazine Maleate 5 mg
88	165	1082a	Tramadol Inj- Each ml to contain: Tramadol Hydrochloride 50mg, 1mlAmp
89	165	1375a	Leflunomide 10mg Tab/Cap-Each Tab/Cap to contain: Leflunomide 10mg
90	165	1497a	Esomeprazole Tab/Cap - Each Plain/Gastro Resistant Tab/Cap To contain: Esomeprazole Magnesium 20 mg
91	165	1497b	Esomeprazole Tab/Cap - Each Plain/Gastro Resistant Tab/Cap to contain: Esomeprazole Magnesium 40 mg
92	165	15b	Hyoscine Butyl Bromide Inj- Each ml to contain: Hyoscine Butyl Bromide 20mg., 1ml Amp
93	165	567b	Rabeprazole Tab/Cap - Each Plain/Gastro Resistant Tab/Cap to contain: Rabeprazole 20 mg.

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Hindustan Laboratories Limited	21	Furazolidone Susp-Each 5ml to contain: Furazolidone 25mg, 60ml Bottle	1ml	Same as in Item	60ml Bottle	0.22/1ml	Paise Twenty Two Only	L-1
165	Abbott Healthcare Pvt Ltd	25	Metronidazole Susp-Each 5ml to contain: Metronidazole 200mg, 60ml Bottle	1ml	Flagyl Suspension	60ml Bottle	0.26/1ml	Paise Twenty Six Only	L-1 (50% of Order Quantity)
165	Hindustan Laboratories Limited	25	Metronidazole Susp-Each 5ml to contain: Metronidazole 200mg, 60ml Bottle	1ml	FLONIDAZOLE	60ml Bottle	0.26/1ml	Paise Twenty Six Only	L-1 (50% of Order Quantity)
165	J B Chemicals & Pharmaceuticals Ltd	25	Metronidazole Susp- Each 5ml to contain: Metronidazole 200mg, 60ml Bottle	1ml	METROGYL	60ml Bottle	0.28/1ml	Paise Twenty-Eight Only	L-2
165	RIVPRA FORMULATION PVT. LTD.	318	Naproxen Tab/Cap-Each Tab/Cap to contain: Naproxen 250mg.	1 Tab/Cap	Same as in Item	15 Tab	1.23/1 Tab	Rupee One Paise Twenty Three Only	L-1
165	MICRON PHARMACEUTICALS	318	Naproxen Tab/Cap-Each Tab/Cap to contain: Naproxen 250mg.	1 Tab/Cap	Same as in Item	10 Tab	1.36/1 Tab	Rupee One Paise Thirty Six Only	L-2
165	Cipla Ltd.	387	Ondansetron Tab/Cap-Each Tab/Cap to contain: Ondansetron 4mg.	1 Tab/Cap	EMESET-4	10 Tab	0.24/1 Tab	Paise Twenty Four Only	L-1
165	GALPHA LABORATORIES LIMITED	387	Ondansetron Tab/Cap-Each Tab/Cap to contain: Ondansetron 4mg.	1 Tab/Cap	ISV 4 MD	10 Tab	0.45/1 Tab	Paise Forty Five Only	L-2
165	MANKIND PHARMA LIMITED	387	Ondansetron Tab/Cap-Each Tab/Cap to contain: Ondansetron 4mg.	1 Tab/Cap	VOMIKIND-MD 4	10 Tab	0.52/1 Tab	Paise Fifty Two Only	L-3
165	Abbott India Limited	415	Laxative Liquid - Each. 5 ml. to contain: Liquid Parafin 1.25ml., Milk of Magnesia 3.75ml., Sodium Picosulphate 3.33mg. Packing-110 to 200ml Bottle	1ml	CREMAFFIN PLUS	110ml Bottle	0.15/1ml	Paise Fifteen Only	L-1 (50% of Order Quantity)

ESIC

(Handwritten Signature)

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	MICRON PHARMACEUTICALS	415	Laxative Liquid-Each. 5 ml. to contain: Liquid Parafin 1.25ml., Milk of Magnesia 3.75ml., Sodium Picosulphate 3.33mg. Packing-110 to 200ml Bottle	1ml	Same as in Item	170ml Bottle	0.15/1ml	Paise Fifteen Only	L-1 (50% of Order Quantity)
165	MDC PHARMACEUTICALS LIMITED	415	Laxative Liquid-Each. 5 ml. to contain: Liquid Parafin 1.25ml., Milk of Magnesia 3.75ml., Sodium Picosulphate 3.33mg. Packing-110 to 200ml Bottle	1ml	Same as in Item	200ml Bottle	0.17/1ml	Paise Seventeen Only	L-2
165	Hindustan Laboratories Limited	415	Laxative Liquid-Each. 5 ml. to contain: Liquid Parafin 1.25ml., Milk of Magnesia 3.75ml., Sodium Picosulphate 3.33mg. Packing-110 to 200ml Bottle	1ml	HIRELAX	200ml Bottle	0.19/1ml	Paise Nineteen Only	L-3
165	Raptakos, Brett & Company Limited	417	Enzyme Drop- Each ml to contain: Alpha-Amylase (Bacterial 1:800) 20mg, Papain 10mg, Dill Oil 2mg, Anise Oil 2mg, Caraway Oil 2mg.,15ml Bottle	1ml	Neopeptine Drops	15ml Bottle	4.98/1ml	Rupees Four Paise Ninety Eight Only	L-1
165	Raptakos, Brett & Company Limited	418	Enzyme Syp- Each 15ml to contain: Iodised Peptone 29 mg, Mag. Chl 20 mg, Mang. Sulph. 4mg, Zn. Sulph. 6 mg, Sod. Metavandate 0.66 mg, Pyridoxine Hd 0.75mg., Cyanocobalamin 0.5mcg, Nicotinamide 10mg, Alcohol 0.95 ml,300ml Bottle	1ml	Elixir Neogadine-RB	300ml Bottle	0.38/1ml	Paise Thirty Eight Only	L-1
165	Wings Biotech LLP	478	Lactulose Syp-Each 15 ml to contain Lactulose 10gm., Packing-100ml to 150ml Bottle	1ml	Same as in Item	200ml Bottle	0.44/1ml	Paise Forty Four Only	L-1
165	Hindustan Laboratories Limited	478	Lactulose Syp-Each 15 ml to contain Lactulose 10gm. Packing-100ml to 150ml Bottle	1ml	HI-CTULOSE	150ml Bottle	0.48/1ml	Paise Forty Eight Only	L-2

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Windlas Biotech Limited	478	Lactulose Symp - Each 15 ml to contain Lactulose 10gm. Packing-100ml to 150ml Bottle	1ml	Lactuwin	150ml Bottle	0.82/1ml	Paise Eighty Two Only	L-3
165	HAB Pharmaceuticals & Research Ltd	482	Cipro + Dexamethasone Eye Drop-Each Vial to contain: Ciprofloxacin 0.3%, Dexamethasone 0.1%, Benzalkonium Chloride 0.01%, Packing: 5ml to 10ml Vial	1ml	CYFLOX-D	10ml Drop	0.97/1ml	Paise Ninety Seven Only	L-1
165	ALPA LABORATORIES LTD	482	Cipro + Dexamethasone Eye Drop-Each Vial to contain: Ciprofloxacin 0.3%, Dexamethasone 0.1%, Benzalkonium Chloride 0.01%, Packing: 5ml to 10ml Vial	1ml	Same as in Item	5ml Drop	2/1ml	Rupees Two Only	L-2
165	Heal (India) Laboratories Pvt. Ltd.	534	Pre & Probiotic Tab/ Cap-Each Tab/Cap to contain: Streptococcus faecalis 30 million, Clostridium butyricum 2 million, Bacillus mesentericus 1 million, Lactic acid bacillus sporogenes 50 million.	1 Tab/Cap	NATUROBACT	10 Cap	1.39/1 Cap	Rupee One Paise Thirty Nine Only	L-1
165	Morepen Laboratories Limited	534	Pre & Probiotic Tab/ Cap- Each Tab/Cap to contain: Streptococcus faecalis 30 million, Clostridium butyricum 2 million, Bacillus mesentericus 1 million, Lactic acid bacillus sporogenes 50 million.	1 Tab/Cap	Regermina	10 Cap	1.58/1 Cap	Rupee One Paise Fifty Eight Only	L-2
165	Med Manor Organics Pvt. Ltd.	534	Pre & Probiotic Capsules, Each Capsule contains: Streptococcus faecalis 30 million, Clostridium butyricum 2 million, Bacillus mesentericus 1 million, Lactic acid bacillus sporogenes 50 million.	1 Tab/Cap	Pre 4	10 Cap	1.64/1 Cap	Rupee One Paise Sixty Four Only	L-3

ESIC

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Primus Pharmaceuticals	551	Clotrimazole + Lignocaine Ear Drop-Each Bottle to contain: Clotrimazole 1%, Lignocaine Hydrochloride 2%, 10ml Bottle	1ml	OTITUS	10ml Drop	1.43/1ml	Rupee One Paise Forty Three Only	L-1
165	DWD Pharmaceuticals Ltd.	551	Clotrimazole + Lignocaine Ear Drop-Each Bottle to contain: Clotrimazole 1% , Lignocaine Hydrochloride 2%,10ml Bottle	1ml	DREP-C EAR DROPS	10ml Drop	1.68/1ml	Rupee One Paise Sixty Eight Only	L-2
165	Glenmark Pharmaceuticals Limited	551	Clotrimazole + Lignocaine Ear Drop-Each Bottle to contain: Clotrimazole 1%, Lignocaine Hydrochloride 2%,10ml Bottle	1 ml	Candid Ear Drop	10ml Drop	1.72/1ml	Rupee One Paise Seventy Two Only	L-3
165	LUPIN LIMITED	1029	Enzyme Tab/Cap-Each Tab/Cap to contain: Pepsin (1:3000) 12.5 mg., Fungal Diastase (1:2000) 18.75 mg	1 Tab/Cap	LUPIZYME CAPSULES	10 Cap	1.49/1 Cap	Rupee One Paise Forty Nine Only	L-1
165	ALPA LABORATORIES LTD	1096	Paracetamol Inj-Each ml to contain: Paracetamol 150mg, 2ml Amp	1 Vial/Amp	Same as in Item	2ml Amp	6.22/1 Amp	Rupees Six Paise Twenty Two Only	L-1
165	Wings Biotech LLP	1098	Allopurinol Tab/Cap-Each Tab/Cap to contain: Allopurinol 100 mg.	1 Tab/Cap	Same as in Item	10 Tab	0.53/1 Tab	Paise Fifty Three Only	L-1
165	Med Manor Organics Pvt. Ltd.	1107	Serratiopeptidase Tablets, Each Tablet Contains: Serratiopeptidase 5mg (10,000 Units Of Serratiopeptidase)	1 Tab/Cap	Spade	10 Tab	0.72/1 Tab	Paise Seventy Two Only	L-1
165	Centaur Pharmaceuticals Pvt. Ltd.	1228	Acyclovir Eye Oint-Each Tube to contain: Acyclovir I.P.3%,5gm Tube	1gm	EYEVIR	4.5g Tube	9.2/1gm	Rupees Nine Paise Twenty Only	L-1
165	Hindustan Laboratories Limited	1240	Choline Salicylate Gel-Containing : Choline Salicylate 9.0% w/v, Benzalkonium Chloride 0.02%, 10ml Tube/Bottle	1ml	HINCHOLINE GEL	10ml Tube	2.96/1ml	Rupees Two Paise Ninety Six Only	L-1


ESIC

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Med Manor Organics Pvt. Ltd.	1240	Choline Salicylate Gel-Containing : Choline Salicylate 9.0% w/v, Benzalkonium Chloride 0.02%,10ml Tube/Bottle	1ml	Dentacain Plus	10ml Bottle	3.4/1ml	Rupees Three Paise Forty Only	L-2
165	Raptakos, Brett & Company Limited	1240	CHOLINE SALICYLATE GEL, Containing : Choline Salicylate BP 9.0% w/v, Benzalkonium Chloride IP 0.02% w/v	1ml	Zytee RB	10ml Tube	4.67/1ml	Rupees Four Paise Sixty Seven Only	L-3
165	Tablets (India) Limited	1413	Antacid Sachet- Each Sachet (0.67g) to contain: Water Soluble Azulene (Sodium Azulenesulfonate) JPC 2.01 mg, L- Glutamine JPC 663.3 Mg	1 Sachet	Glutazene Sachet	1 Sachet	10.34/ 1 Sachet	Rupees Ten Paise Thirty Four Only	L-1
165	Tablets (India) Limited	1414	Prebiotic And Probiotic Sachet- Each Sachet (0.5gm) contains: Streptococcus faecalis T-110 30million Clostridium butyricum To-A 2million bacillus mesentericus To A 1 Million Lactic Acid bacillus 50 million (Lactobacillus sporogenes)	1 Sachet	Bifilac Sachet	1 Sachet	7.33/ 1 Sachet	Rupees Seven Paise Thirty Three Only	L-1
165	Hindustan Laboratories Limited	1418	Thiocolchicoside Tab/Cap-Each Tab/Cap to contain: Thiocolchicoside 8mg	1 Tab/Cap	HICOSIDE	10 Cap	4.50/1 Cap	Rupees Four Paise Fifty Only	L-1 (50% of Order Quantity)
165	Morepen Laboratories Limited	1418	Thiocolchicoside Tab/Cap-Each Tab/Cap to contain: Thiocolchicoside 8mg	1 Tab/Cap	Thiodoc 8	10 Cap	4.50/1 Cap	Rupees Four Paise Fifty Only	L-1 (50% of Order Quantity)
165	Primus Pharmaceuticals	1418	Thiocolchicoside Tab/Cap-Each Tab/Cap to contain: Thiocolchicoside 8mg	1 Tab/Cap	THIOPRIME-8	10 Tab	4.59/1 Cap	Rupees Four Paise Fifty Nine Only	L-2
165	LOGOS PHARMA	1418	Thiocolchicoside Tab/Cap-Each Tab/Cap to contain: Thiocolchicoside 8mg	1 Tab/Cap	Same as in Item	10 Tab	4.75/1 Tab	Rupees Four Paise Seventy Five Only	L-3
165	Primus Pharmaceuticals	1432	Olopatadin Eye Drop-Each ml to contain: Olopatadin 1.0mg,5ml Vial	1ml	OLORUS	5ml Drop	2.20/1ml	Rupees Two Paise Twenty Only	L-1

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Ajanta Pharma Ltd.	1432	Olopatadin Eye Drop- Each ml to contain: Olopatadin 1.0mg,5ml Vial	1ml	Olopat Eye Drops	5ml Drop	2.45/1ml	Rupees Two Paise Forty Five Only	L-2
165	HAB Pharmaceuticals & Research Ltd	1432	Olopatadin Eye Drop-Each ml to contain: Olopatadin 1.0mg,5ml Vial	1ml	Same as in Item	5ml Drop	2.58/1ml	Rupees Two Paise Fifty Eight Only	L-3
165	UNICURE INDIA LTD	1496	Rabeprazole Sodium + Mosapride Citrate Tab/Cap- Each Tab/Cap to contain: Rabeprazole Sodium 20mg, Mosapride Citrate 15mg Sustained Release	1 Tab/Cap	Same as in Item	10 Cap	2.38/1 Cap	Rupees Two Paise Thirty Eight Only	L-1
165	Med Manor Organics Pvt. Ltd.	1496	Rabeprazole Sodium + Mosapride Citrate Tab/Cap- Each Tab/Cap to contain: Rabeprazole Sodium 20mg, Mosapride Citrate 15mg Sustained Release	1 Tab/Cap	Rabnor-M	10 Cap	2.88/1 Cap	Rupees Two Paise Eighty Eight Only	L-2
165	Torrent Pharmaceuticals Ltd.	1496	Rabeprazole Sodium + Mosapride Citrate Tab/Cap- Each Tab/Cap to contain: Rabeprazole Sodium 20mg, Mosapride Citrate 15mg Sustained Release	1 Tab/Cap	VELOZ M	10 Cap	4.00/1 Cap	Rupees Four Only	L-3
165	Tablets (India) Limited	1506	Bacillus Clausii Spores Susp - Each 5ml to contain: Bacillus clausii spores 2 Billion spores, susp.in 5ml distilled water,5ml pack	1ml	Bifilac Clausi	5ml Mini Bottle	3.36/1ml	Rupees Three Paise Thirty Six Only	L-1
165	Tablets (India) Limited	1507	Pre & Probiotic Tab/Cap- Each Tab/Cap.to contain: Streptococcus Faecalis T - 110 60 Million, Clostridium Butyricum TO-A 4 Million, Bacillus Mesentericus TO-A 2 Million, Lactic Acid Bacillus 100 Million. (Lactobacillus Sporogenes)	1 Tab/Cap	Bifilac HP	10 Cap	8.25/1 Cap	Rupees Eight Paise Twenty Five Only	L-1
165	Morepen Laboratories Limited	1543	Diacerein Tab/Cap- Each Tab/Cap to contain: Diacerein 50mg	1 Tab/Cap	MORECERIN	10 Cap	1.84/1 Cap	Rupee One Paise Eighty Four Only	L-1


 30 | Page

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Macleods Pharmaceuticals Limited	1543	Diacerein Tab/Cap-Each Tab/Cap to contain: Diacerein 50mg	1 Tab/Cap	ORCERIN	10 Cap	2.36/1 Cap	Rupees Two Paise Thirty Six Only	L-2
165	Glenmark Pharmaceuticals Limited	1595	Levofloxacin Eye Drop-Containing: Levofloxacin soln. 0.5%,5ml Vial	1ml	GLEVO EYE/EAR DROPS 0.5% W/V	5ml Drop	3.06/1ml	Rupees Three Paise Six Only	L-1
165	HAB Pharmaceuticals & Research Ltd	1597	Moxifloxacin Eye Drop-Containing: Moxifloxacin soln. 0.5% w/v,5ml Vial	1ml	MOXISIGN	5ml Drop	1.98/1ml	Rupee One Paise Ninety Eight Only	L-1
165	Ajanta Pharma Ltd.	1597	Moxifloxacin Eye Drop -Containing: Moxifloxacin soln. 0.5% w/v,5ml Vial	1ml	Apdrops Eye Drops	5ml Drop	2.17/1ml	Rupees Two Paise Seventeen Only	L-2
165	Centaur Pharmaceuticals Pvt. Ltd.	1597	Moxifloxacin Eye Drop-Containing: Moxifloxacin soln. 0.5% w/v,5ml Vial	1ml	CENTAFLOX EYE DROPS	5ml Drop	5.6/1ml	Rupees Five Paise Sixty Only	L-3
165	Centaur Pharmaceuticals Pvt. Ltd.	1599	Moxifloxacin Eye Oint- Each Tube to contain: Moxifloxacin 0.5%,5gm Tube	1gm	CENTAFLOX EYE OINTMENT	5g Tube	6.18/1gm	Rupees Six Paise Eighteen Only	L-1
165	Med Manor Organics Pvt. Ltd.	1655	Ilaprazole Tab/Cap-Each Plain/Gastro Resistant Tab/Cap to contain: Ilaprazole 10mg	1 Tab/Cap	ILANOR-10	10 Tab	1.71/1 Tab	Rupee One Paise Seventy One Only	L-1
165	Signature Phytochemical Industries	1655	Ilaprazole Tab/Cap-Each Plain/Gastro Resistant Tab/Cap to contain: Ilaprazole 10mg	1 Tab/Cap	ILASIGN	10 Tab	1.9/1 Tab	Rupee One Paise Ninety Only	L-2
165	Ajanta Pharma Ltd.	1655	Ilaprazole Tab/Cap - Each Plain/Gastro Resistant Tab/Cap to contain: Ilaprazole 10mg	1 Tab/Cap	ILAPRO 10 MG	10 Tab	1.99/1 Tab	Rupee One Paise Ninety Nine Only	L-3

क.रा.बी.नि.
ESIC

8

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Tablets (India) Limited	1656	Laxative Powder - Each pouch to contain: Polyethylene Glycol 118 gm, Potassium Chloride 1.484 gm, Sodium Bicarbonate 3.37 gm, Sodium Chloride 2.93 gm, Sodium Sulphate 11.36 gm.,137.15 gm pouch	1 Pouch	Peglec	1 Pack (137.15 gm)	158.19/1 Pack	Rupees One Hundred Fifty Eight Paise Nineteen Only	L-1
165	Themis Medicare Limited	1657	Palonosetron Hydrochloride Inj -Each 1.5ml Contains: Palonosetron Hydrochloride equivalent to Palonosetron-0.075 mg water for Inj-q.s.,1.5ml vial	1 Vial	THEMISSET 75 INJ.	1.5ml Vial	125/1 Vial	Rupees One Hundred Twenty Five Only	L-1
165	Hindustan Laboratories Limited	1658	Zinc Syp- Each 5ml to contain: Elemental Zinc 20mg, 100ml Bottle	1ml	ZINCO-20	100 ml Bottle	0.14/1ml	Paise Fourteen Only	L-1 (50% of Order Quantity)
165	Morepen Laboratories Limited	1658	Zinc Syp- Each 5ml to contain: Elemental Zinc 20mg,100ml Bottle	1ml	ZINCOFINE	100 ml Bottle	0.14/1ml	Paise Fourteen Only	L-1 (50% of Order Quantity)
165	UNICURE INDIA LTD	1658	Zinc Syp-Each 5ml to contain: Elemental Zinc 20mg,100ml Bottle	1ml	Same as in Item	100ml Bottle	0.15/1ml	Paise Fifteen Only	L-2
165	MDC PHARMACEUTICALS LIMITED	1658	Zinc Syp Each 5ml to contain: Elemental Zinc 20mg,100ml Bottle	1ml	Same as in Item	100ml Bottle	0.18/1ml	Paise Eighteen Only	L-3
165	Glenmark Pharmaceuticals Limited	1675	Lornoxicam SR Tab/Cap-Each SR Tab/Cap to contain: Lornoxicam 16 Mg	1 Tab/Cap	Flexilor SR	10 Tab	3.16/1 Tab	Rupees Three Paise Sixteen Only	L-1 (50% of Order Quantity)
165	Tirupati Medicare Ltd.	1675	Lornoxicam SR Tab/Cap, Each SR Tab/Cap to contain: Lornoxicam 16 Mg	1 Tab/Cap	Trulord	10 Tab	3.16/1 Tab	Rupees Three Paise Sixteen Only	L-1 (50% of Order Quantity), Class-I Local Supplier

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Tablets (India) Limited	1742	Pre & Probiotic And Oral Rehydration Sachet- Each Pack-in-Pack Sachet WHO ORS Pack 4.10g contains: Sodium Chloride 0.52gm,Sodium Citrate 0.58gm,Potassium Chloride 0.3gm,Dextrose Anhydrous 2.7gm Pre & Probiotic Pack 0.5g contains: Streptococcus Faecalis T-110 7.5 Million,Clostridium Butyricum TO-A 0.5 Million,Bacillus Mesentericus TO-A 0.25 Million,Lactobacillus Sporogenes 20.0 Million.	1 Sachet	BioRS Sachet	1 Sachet	10.5/1 Sachet	Rupees Ten Paise Fifty Only	L-1
165	Healer's Lab	1757	Etoricoxib Tab/Cap - Each Tab/Cap to contain: Etoricoxib 90 mg	1 Tab/Cap	ETX-90	10 Tab	1.00/1 Tab	Rupee One Only	L-1
165	Overseas Health Care Private Limited	1757	Etoricoxib Tab/Cap -Each Tab/Cap to contain: Etoricoxib 90 mg	1 Tab/Cap	TORIB-90	15 Tab	1.04/1 Tab	Rupee One Paise Four Only	L-2
165	Wings Biotech LLP	1757	Etoricoxib Tab/Cap - Each Tab/Cap to contain: Etoricoxib 90 mg	1 Tab/Cap	Same as in Item	10 Tab	1.07/1 Tab	Rupee One Paise Seven Only	L-3
165	SANOFI HEALTHCARE INDIA PRIVATE LIMITED	1760	Hylan G-F20 Injection - Each contain: Hylan G-F20 ,6ml PFS.	1 PFS	SYNVISC ONE (Mfd. by M/s Genzyme Corporation a Sanofi Company, USA)	6ml Prefilled Syringe	14840/1 PFS	Rupees Fourteen Thousand Eight Hundred Forty Only	L-1
165	UNICURE INDIA LTD	1824	Lactulose Granules -Each 15gm of granules to contain : Lactulose BP 10 gm, Ispaghula Husk IP 3.50 gm, Pack of 90 Gram	1gm	same as in Item	Pack of 90gm	1.82/1gm	Rupee One Paise Eighty Two Only	L-1

ESIC

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Hindustan Laboratories Limited	1824	Lactulose Granules -Each 15gm of granules to contain : Lactulose BP 10 gm, Ispaghula Husk IP 3.50 gm, Pack of 90 Gram	1gm	SMOOTH RELIEF	Pack of 90 Gram	2.95/1gm	Rupees Two Paise Ninety Five Only	L-2
165	Themis Medicare Limited	1865	Tolperisone & Diclofenac Tab/Cap - Each film coated Tab/Cap to contain: Tolperisone Hydrochloride JP 150mg + Diclofenac Sodium IP 50mg, Excipients-q.s	1 Tab/Cap	TOLPIDOL-D	10 Tab	2.64/1 Tab	Rupees Two Paise Sixty Four Only	L-1
165	HAB Pharmaceuticals & Research Ltd	1865	Tolperisone & Diclofenac Tab/Cap - Each film coated Tab/Cap to contain: Tolperisone Hydrochloride JP 150mg + Diclofenac Sodium IP 50mg, Excipients q.s	1 Tab/Cap	TOLAREX-D	10 Tab	3.68/1 Tab	Rupees Three Paise Sixty Eight Only	L-2
165	Windlas Biotech Limited	1865	Tolperisone & Diclofenac Tab/Cap - Each film coated Tab/Cap to contain: Tolperisone Hydrochloride JP 150mg + Diclofenac Sodium IP 50mg, Excipients q.s	1 Tab/Cap	Tolfenac	10 Tab	4.00/1 Tab	Rupees Four Only	L-3
165	Biodeal Pharmaceuticals Ltd.	1935	Fluticasone Nasal Spray - Each spray delivers Fluticasone Propionate IP 50mcg to contain: Fluticasone Propionate IP - 0.05% w/v, Benzalkonium Chloride IP - 0.01% w/v (as preservative) Phenyl Ethyl Alcohol Usp - 0.25% w/v (as preservative), 100 MD	1 Metered Dose	Same as in Item	10ml (100 Metered Dose)	0.37/1 MD	Paise Thirty Seven Only	L-1

क.स.बी.नि.
ESIC

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	HAB Pharmaceuticals & Research Ltd	1935	Fluticasone Nasal Spray- Each spray delivers Fluticasone Propionate IP 50mcg to contain: Fluticasone Propionate IP - 0.05% w/v, Benzalkonium Chloride IP - 0.01% w/v (as preservative) Phenyl Ethyl Alcohol Usp - 0.25% w/v (as preservative),100 MD	1 Metered Dose	FLOSIGN	10ml Spray (100 Metered Dose)	0.47/1 MD	Paise Forty Seven Only	L-2
165	Biodeal Pharmaceuticals Ltd.	2010	Pantaprazole 40mg + Domperidone 30 mg SR Tab - Each Tab/Cap to contain: Pantaprazole 40mg + Domperidone (SR) 30 mg	1 Tab/Cap	Same as in Item	10 Cap	0.79/1 Cap	Paise Seventy Nine Only	L-1
165	RIVPRA FORMULATION PVT. LTD.	2010	Pantaprazole 40mg + Domperidone 30 mg SR Tab-Each Tab/Cap to contain: Pantaprazole 40mg + Domperidone (SR) 30 mg	1 Tab/Cap	PANTORIK-DSR	10 Cap	0.89/1 Cap	Paise Eighty Nine Only	L-2
165	ULTRA DRUGS PVT. LTD.	2010	Pantaprazole 40mg + Domperidone 30 mg SR Tab - Each Tab/Cap to contain: Pantaprazole 40mg + Domperidone (SR) 30 mg	1 Tab/Cap	Same as in Item	10 Cap	0.93/1 Cap	Paise Ninety Three Only	L-3
165	Tablets (India) Limited	2012	Pre & Probiotic Dry Syp - Each 5 ml to contains: Streptococcus faecalis T-110 30 millionClostridium butyricum TO-A 2 millionBacillus mesentericus TO-A 1 millionLactic acid bacillus (Lactobacillus sporogenes) 50 millionExcipients q.s.50ml Bottle	1ml	Bifilac Dry Syrup	50ml Bottle	1.39/1ml	Rupee One Paise Thirty Nine Only	L-1
165	Zydus Lifesciences Limited	2029	Teriparatide 750 mcg Inj - Each 3ml cartridge to contain : Teriparatide 750 mcg	1 Cartridge	BONMAX PTH	3ml Pre-filled Pen Device	1139/1 Cartridge	Rupees One Thousand One Hundred Thirty Nine Only	L-1 (50% of Order Quantity)

ESIC

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Intas Pharmaceuticals Ltd.	2029	Teriparatide 750 mcg Inj - Each 3ml cartridge to contain : Teriparatide 750 mcg	1 Cartridge	TERIFRAC	3ml Pre-filled Cartridge	1139/1 Cartridge	Rupees One Thousand One Hundred Thirty Nine Only	L-1 (50% of Order Quantity), Class-I Local Supplier
165	Virchow Biotech Pvt. Ltd.	2029	Teriparatide 750 mcg Inj - Each 3ml cartridge to contain : Teriparatide 750 mcg	1 Cartridge	Osteotide	3ml Pre-filled Pen Device	1680/1 Cartridge	Rupees One Thousand Six Hundred Eighty Only	L-3
165	MANKIND PHARMA LIMITED	2059	Silymarin Tab/Cap-Each Film Coated Tab/Cap to contain: Metadoxine 500mg, Silymarin 140mg, L-Ornithine L-Aspartate 150mg, Pyridoxine Hydrochloride 3mg, Folic Acid 1.5mg	1 Tab/Cap	HEPAGIFT	10 Tab	9.90/1 Tab	Rupees Nine Paise Ninety Only	L-1
165	Windlas Biotech Limited	2059	Silymarin Tab/CapEach Film Coated Tab/Cap to contain: Metadoxine 500mg, Silymarin 140mg, L-Ornithine L-Aspartate 150mg, Pyridoxine Hydrochloride 3mg, Folic Acid 1.5mg	1 Tab/Cap	LIVPROTEK	10 Tab	10.30/1 Tab	Rupees Ten Paise Thirty Only	L-2
165	Med Manor Organics Pvt. Ltd.	2059	Silymarin Tab/Cap-Each Film Coated Tab/Cap to contain: Metadoxine 500mg, Silymarin 140mg, L-Ornithine L-Aspartate 150mg, Pyridoxine Hydrochloride 3mg, Folic Acid 1.5mg	1 Tab/Cap	B-Liv Forte	10 Tab	13.50/1 Tab	Rupees Thirteen Paise Fifty Only	L-3
165	Emcure Pharmaceuticals Limited	2082	Dexketoprofen + Paracetamol Tab/Cap-Each Tab/Cap to contain: Dexketoprofen 25mg, Paracetamol 325mg	1 Tab/Cap	Infen-P	10 Tab	6.70/1 Tab	Rupees Six Paise Seventy Only	L-1

ESIC

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Bayer Pharmaceuticals Private Limited	2083	Aflibercept Injection 40 Mg / Ml Aflibercept (R-DNA Origin) Solution For Intravitreal Injection in Vial Each Pack to contain: 1 Vial and a 18 G Sterile Filter Needle 278 Microliters/Vial Each Single Dose Vial Provides A Usable Amount To Deliver A Single Dose Of 50 Microliters Containing 2mg Aflibercept.	1 Vial	Inj. Eylea 40mg/ml (Mfd. by Bayer AG, Mullerstrasse 178, D-13353 Berlin Germany)	1 vial	40495/1 Vial	Rupees Forty Thousand Four Hundred Ninety Five Only	L-1
165	MICRON PHARMACEUTICALS	2187	Antacid Tab/Cap-Each Uncoated Tab/Cap to contain: Dried Aluminium Hydroxide I.P. 240 mg, Magnesium Hydroxide I.P. 100 mg, Activated Dimethicone I.P 25 mg, Light Magnesium Carbonate I.P 60 mg.	1 Tab/Cap	MILUCID	10 Tab	0.36/1 Tab	Paise Thirty Six Only	L-1
165	Wallace Pharmaceuticals Pvt. Ltd.	2187	Antacid Tab/Cap-Each Uncoated Tab/Cap to contain: Dried Aluminium Hydroxide I.P. 240 mg, Magnesium Hydroxide I.P. 100 mg, Activated Dimethicone I.P 25 mg, Light Magnesium Carbonate I.P 60 mg.	1 Tab/Cap	DIOVOL TABLET	12 Tab	0.40/1 Tab	Paise Forty Only	L-2
165	UNICURE INDIA LTD	2187	Antacid Tab/Cap-Each Uncoated Tab/Cap to contain: Dried Aluminium Hydroxide I.P. 240 mg, Magnesium Hydroxide I.P. 100 mg, Activated Dimethicone I.P 25 mg, Light Magnesium Carbonate I.P 60 mg.	1 Tab/Cap	Same as in Item	10 Tab	0.42/1 Tab	Paise FortyTwo Only	L-3
165	Med Manor Organics Pvt. Ltd.	2192	Resistant Bacillus Clausii Tab/Cap: Each Tab/Cap Contains:2 billion spores of polyantibiotic- Resistant Bacillus Clausii	1 Tab/Cap	Medogermina	10 Cap	16.20/1 Cap	Rupees Sixteen Paise Twenty Only	L-1

ESIC

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	MODI MUNDIPHARMA PVT LTD	2198	Each PFS to contain: Sodium Hyaluronate BP 80mg to 90mg (Cross Linked) Phosphate Buffer Saline Q.S., 1 PFS	1mg	MONOVISC (Mfd. by Anika Therapeutics Inc., USA)	88mg in 4ml Pre Filled Syringe	107.95/1mg	Rupees One Hundred Seven Paise Ninety Five Only	L-1
165	MESMER PHARMACEUTICALS	2199	Badofen Tab/Cap-Each Tab/Cap to contain: Badofen 10 mg	1 Tab/Cap	BACFEN-10	10 Tab	0.54/1 Tab	Paise Fifty Four Only	L-1
165	HAB Pharmaceuticals & Research Ltd	2199	Badofen Tab/Cap-Each Tab/Cap to contain: Badofen 10 mg	1 Tab/Cap	BACLOSIGN-10	10 Tab	1.90/1 Tab	Rupee One Paise Ninety Only	L-2
165	Ipca Laboratories Ltd.	2250	Ondansetron Tab/Cap-Each Tab/Cap to contain: Ondansetron 8mg.	1 Tab/Cap	Periset-8	10 Tab	1.35/1 Tab	Rupee One Paise Thirty Five Only	L-1
165	MDC PHARMACEUTICALS LIMITED	2255	Sodium Picosulphate Tab/Cap-Each Tab/Cap to contain: Sodium Picosulphate 10 mg	1 Tab/Cap	Same as in Item	10 Tab	0.86/1 Tab	Paise Eighty Six Only	L-1
165	Signature Phytochemical Industries	2261	Aceclofenac & Tizanidine Tab/Cap-Each Tab/Cap to contain: Aceclofenac 100mg, Tizanidine 2mg	1 Tab/Cap	TRINEX-ACE	10 Tab	1.89/1 Tab	Rupee One Paise Eighty Nine Only	L-1
165	MDC PHARMACEUTICALS LIMITED	2261	Aceclofenac & Tizanidine Tab/Cap-Each Tab/ Cap to contain: Aceclofenac 100mg, Tizanidine 2mg	1 Tab/Cap	Same as in Item	10 Tab	2.10/1 Tab	Rupees Two Paise Ten Only	L-2
165	Wings Biotech LLP	2261	Aceclofenac & Tizanidine Tab/Cap- Each Tab/ Cap to contain: Aceclofenac 100mg, Tizanidine 2mg	1 Tab/Cap	Same as in Item	10 Tab	2.32/1 Tab	Rupees Two Paise Thirty Two Only	L-3
165	MICRO LABS LTD	2276	Polyethylene Glycol & Propylene Glycol Eye Drop- Each Vial to contain: Polyethylene Glycol 400 0.4%, Propylene Glycol 0.3%,10ml Vial	1ml	MOISTANE EYE DROPS	10ml Drop	9.20/1ml	Rupees Nine Paise Twenty Only	L-1
165	LUPIN LIMITED	2276	Polyethylene Glycol & Propylene Glycol Eye Drop- Each Vial to contain: Polyethylene Glycol 400 0.4%, Propylene Glycol 0.3%,10ml Vial	1ml	LUPIN'S SENSIEYES PLUS EYE DROP	10ml Drop	9.49/1ml	Rupees Nine Paise Forty Nine Only	L-2

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Primus Pharmaceuticals	2279	Fluorometholone + Tobramycin Eye Drop-Each ml to contain: Fluorometholone 0.1% w/v, Tobramycin 0.3% w/v ,5ml Vial	1ml	T- FLO	5ml Drop	9.80/1ml	Rupees Nine Paise Eighty Only	L-1
165	Primus Pharmaceuticals	2283	Natamycin Eye Drop-Each ml to contain: Natamycin 5% w/v,5ml Vial	1ml	NATAPRIME	5ml Drop	9.80/1ml	Rupees Nine Paise Eighty Only	L-1
165	ALPA LABORATORIES LTD	2291	Ofloxacin + Dexamethasone Eye Drop: Each ml to contain: Ofloxacin 0.3%, Dexamethasone 0.1%, 10ml Vial	1ml	Ofloxacin and Dexamethasone Ophthalmic Solution	10ml Drop	1.94/1ml	Rupee One Paise Ninety Four Only	L-1
165	HAB Pharmaceuticals & Research Ltd	2291	Ofloxacin + Dexamethasone Eye Drop: Each ml to contain: Ofloxacin 0.3%, Dexamethasone 0.1%, 10ml Vial	1ml	FLOX-O-DEX	10ml Drop	1.98/1ml	Rupee One Paise Ninety Eight Only	L-2
165	RIVPRA FORMULATION PVT. LTD.	2297	Sodium Bicarbonate Tab/Cap-Each Tab/Cap to contain: Sodium Bicarbonate 500mg	1 Tab/cap	Same as in Item	10 Tab	0.76/1 Tab	Paise Seventy Six Only	L-1
165	LOGOS PHARMA	2418	Metaxalone +Diclofenac Potassium Tab/Cap- Each Tab/Cap contain: Metaxalone 400mg +Diclofenac Potassium 50mg	1 Tab/Cap	Same as in Item	10 Tab	7.50/1 Tab	Rupees Seven Paise Fifty Only	L-1
165	MDC PHARMACEUTICALS LIMITED	2418	Metaxalone +Diclofenac Potassium Tab/CapEach Tab/Cap contain: Metaxalone 400mg +Diclofenac Potassium 50mg	1 Tab/Cap	Same as in Item	10 Tab	7.85/1 Tab	Rupees Seven Paise Eighty Five Only	L-2
165	HAB Pharmaceuticals & Research Ltd	2418	Metaxalone +Diclofenac Potassium Tab/Cap- Each Tab/Cap contain: Metaxalone 400mg +Didofenac Potassium 50mg	1 Tab/Cap	OSTERALOX-D	10 Tab	8.60/1 Tab	Rupees Eight Paise Sixty Only	L-3

ESIC

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Glenmark Pharmaceuticals Limited	2420	Fosapretant Dimeglumine inj-Each Vial/Amp to contain: Fosapretant Dimeglumine inj 150mg	1 Vial	Aprecap IV	1 Vial	424/1 Vial	Rupees Four Hundred Twenty Four Only	L-1
165	Ajanta Pharma Ltd.	2425	Loteprednol Etabonate Drop-Each Vial/Phial to contain: Loteprednol Etabonate 0.5%,5ml Vial	1ml	LOTEL GEL	5ml Drop	11.80/1ml	Rupees Eleven Paise Eighty Only	L-1
165	Nanz Medscience Pharma Pvt. Ltd.	2426	Povidone Iodine Mouth Gargle-Each Bottle to contain: Povidone Iodine 2%, 100ml Bottle	1ml	POVINANZ GARGLE	100ml Bottle	0.27/1ml	Paise Twenty Seven Only	L-1
165	Med Manor Organics Pvt. Ltd.	2427	Triamcinolone Acetonide-Each Tube to contain: Triamcinolone Acetonide 0.1 % Paste, 5gm Tube	1gm	Amcinol	5gm Tube	5.22/1gm	Rupees Five Paise Twenty Two Only	L-1
165	Troikaa Pharmaceuticals Limited	2427	Triamcinolone Acetonide-Each Tube to contain: Triamcinolone Acetonide 0.1 % Paste,5gm Tube	1gm	Tess	5gm Tube	5.40/1gm	Rupees Five Paise Forty Only	L-2
165	LOGOS PHARMA	2533	Acotiamide Tab/Cap: Each SR/ER/Plain Tab/Cap to contain Acotiamide 300mg	1 Tab/Cap	Same as in Item	10 Tab	14.00/1 Tab	Rupees Fourteen Only	L-1
165	LOGOS PHARMA	2534	Acotiamide Tab/Cap: Each tab/cap to contain Acotiamide 100mg	1 Tab/Cap	Same as in Item	10 Tab	5.50/1 Tab	Rupees Five Paise Fifty Only	L-1
165	LUPIN LIMITED	2534	Acotiamide Tab/Cap: Each tab/cap to contain Acotiamide 100mg	1 Tab/Cap	LUPIN'S ACOGUT TABLET	15 Tab	6.90/1 Tab	Rupees Six Paise Ninety Only	L-2
165	Centaur Pharmaceuticals Pvt. Ltd.	2540	Chloramphenicol + Dexamethasone + Polymyxin B Eye Ointment: Each gram contains Chloramphenicol (10mg) + Dexamethasone (1mg) + Polymyxin B (10000 IU) ,5gm	1gm	OCUPOL DX	5gm Tube	19.60/1gm	Rupees Nineteen Paise Sixty Only	L-1

ESIC

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	MODI MUNDIPHARMA PVT LTD	2541	Cross linked Sodium Hyaluronate 88mg (22mg/ml) with Triamcinolone hexacetonide 18mg, 4ml Injection BOQ Unit: 1 vial/amp/PFS	1VIAL/AM P/PFS	CINGAL (Mfd. by Anika Therapeutics Inc., USA)	4ml PFS-Pre-Filled Syringe	13500/1 PFS	Rupees Thirteen Thousand Five Hundred Only	L-1
165	Indoco Remedies Ltd.	2544	Policresulen+ Cinchocaine Ointment: Each gram contains: Policresulen 50 mg , Cinchocaine HCL BP 10mg Ointment base q.s,30gm Tube	1gm	Spear Ointment	30gm Tube	6.93/1gm	Rupees Six Paise Ninety Three Only	L-1
165	Morepen Laboratories Limited	2545	Esomeprazole+Levosulpiride:Each Tab/Cap to contain Esomeprazole 40mg+ Levosulpiride 75mg	1 Tab/Cap	Esopen LS	10 Cap	1.24/1 Cap	Rupee One Paise Twenty Four Only	L-1
165	Theon Pharmaceuticals Limited	2545	Esomeprazole+Levosulpiride: Each Tab/Cap to contain Esomeprazole 40mg+ Levosulpiride 75mg	1 Tab/Cap	Same as in Item	10 Cap	2.35/1 Cap	Rupees Two Paise Thirty Five Only	L-2
165	LOGOS PHARMA	2545	Esomeprazole+Levosulpiride:Each Tab/Cap to contain Esomeprazole 40mg+ Levosulpiride 75mg	1 Tab/Cap	Same as in Item	10 Cap	2.50/1 Cap	Rupees Two Paise Fifty Only	L-3
165	Ipca Laboratories Ltd.	2546	Etodolac 400mg Tab/Cap-Each Tab/Cap to contain: Etodolac 400mg	1 Tab/Cap	Etova 400	10 Tab	5.87/1 Tab	Rupees Five Paise Eighty Seven Only	L-1
165	Theon Pharmaceuticals Limited	2547	Etoricoxib+Pregabalin Sustained Release Tablets/cap: Each Tab/Cap to contain Etoricoxib 60mg and Pregabalin 75mg Sustained Release	1 Tab/Cap	Same as in Item	10 Tab	6.36/1 Tab	Rupees Six Paise Thirty Six Only	L-1

क.स.बी.नि.
ESIC

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Overseas Health Care Private Limited	2548	Calcium Carbonate+Magnesium Hydroxide+Famotidine chewable tablet contains: Calcium Carbonate IP 800mg, Magnesium Hydroxide IP 165mg, Famotidine IP 10mg	1 Tab/Cap	PEPDIN	10 Tab	8.91/1 Tab	Rupees Eight Paise Ninety One Only	L-1
165	Roche Products (India) Pvt. Ltd	2549	Faricimab injection contains: Faricimab 6mg/0.05ml Injection	1 Vial/Amp	Vabysmo 6mg/0.05 ml (Mfd. by F. Hoffmann-La Roche AG, Switzerland	1 Vial	52599/1 Vial	Rupees Fifty Two Thousand Five Hundred Ninety Nine Only	L-1
165	LUPIN LIMITED	2550	Flupirtine Maleate Tab/Cap: Each SR/ER/Plain Tab/Cap to contain Flupirtine Maleate 400mg	1 Tab/Cap	FLUGESIC SR TABLET	10 Tab	14.90/1 Tab	Rupees Fourteen Paise Ninety Only	L-1
165	Ajanta Pharma Ltd.	2553	Ketorolac+Moxifloxacin Eye Drop: composition Ketorolac 0.4% w/v +Moxifloxacin 0.5% w/v ,5ml	1ml	APDROPS KT 0.4 EYE DROPS	5ml Drop	16.02/1ml	Rupees Sixteen Paise Two Only	L-1
165	UNICURE INDIA LTD	2554	Lactulose Enema:-Each ml contain Lactulose 200mg, 100ml	1ml	Lactulose Enema 20% w/v	100ml Bottle	0.96/1ml	Paise Ninety Six Only	L-1
165	MICRON PHARMACEUTICALS	2555	Liquid Paraffin, 400ml	1ml	Same as in Item	400ml Bottle	0.24/1ml	Paise Twenty Four Only	L-1
165	Zuventus Healthcare Limited	2556	Mefenamic Acid Syrup: Each 5ml contain Mefenamic acid 100 mg, 60ml bottle	1ml	MEFAST - 100 SUSPENSION	60ml Bottle	0.29/1ml	Paise Twenty Nine Only	L-1
165	MAAN PHARMACEUTICALS LTD.	2558	Nalbuphine injection:Each ampoule contains Nalbuphine 10 mg, 1ml	1 Vial/Amp	Same as in Item	1ml Amp	36.00/1 Amp.	Rupees ThirtySix Only	L-1
165	MAAN PHARMACEUTICALS LTD.	2559	Nalbuphine injection:Each ampoule contains Nalbuphine 20 mg, 1ml	1 Vial/Amp	Same as in Item	1ml Amp	72.00/1 Amp.	Rupees SeventyTwo Only	L-1

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Ajanta Pharma Ltd.	2560	Netarsudil 0.02% Eye Drop: Each ml contain Netarsudil 0.2mg, 2.5ml to 5ml	1ml	NETALO Eye Drops	3ml Drop	66.00/1ml	Rupees Sixty Six Only	L-1
165	ZIM LABORATORIES LIMITED	2561	Pancreatin 25000 tab/cap: Each Tab/Cap to contain Pancreatin 300mg	1 Tab/Cap	PANCREZIM 25000	10 Cap	7.80/1 Cap	Rupees Seven Paise Eighty Only	L-1
165	Biodeal Pharmaceuticals Ltd.	2561	Pancreatin 25000 tab/cap: Each Tab /Cap to contain Pancreatin 300mg	1 Tab/Cap	Same as in Item	10 Cap	12.42/1 Cap	Rupees Twelve Paise Forty Two Only	L-2
165	Troikaa Pharmaceuticals Limited	2562	Paracetamol Injection (IM), 2 mlEach ml contains:Paracetamol IP-250 mg, Absolute Alcohol IP-0% v/v Water for Injections IP-q.s.	1 Vial/Amp	XYKAA-IM	2ml Amp.	20.6/1 Amp.	Rupees Twenty Paise Sixty Only	L-1
165	Ajanta Pharma Ltd.	2563	Ripasudil 0.4% w/v Eye Drops:Each ml contain Ripasudil 4mg, pack of 5ml.	1ml	RIPATEC EYE DROPS	5ml Drop	39.60/ml	Rupees Thirty Nine Paise Sixty Only	L-1
165	Torrent Pharmaceuticals Ltd.	2564	Racecadotril sachet :Each Sachet contain Racecadotril 10mg, 1 g powder/sachet	1 Sachet	ZEDOTT BABY	1gm Sachet	12.06/gm	Rupees Twelve Paise Six Only	L-1
165	Centaur Pharmaceuticals Pvt. Ltd.	2566	Sodium Hyaluronate 0.1% w/v Eye drops, 10ml pack	1ml	HEALTEARS EYE DROPS	10ml Drop	8.70/1ml	Rupees Eight Paise Seventy Only	L-1
165	ULTRA DRUGS PVT. LTD.	2568	Acedofenac 100mg+Paracetamol 325mg+ Serratiopeptidase 15mg Tab/Cap	1 Tab/Cap	Same as in Item	10 Tab	0.92/1 Tab	Paise NinetyTwo Only	L-1
165	Morepen Laboratories Limited	2568	Aceclofenac 100mg+Paracetamol 325mg+ Serratiopeptidase 15mg Tab/Cap	1 Tab/Cap	ZeroDuo-SP	10 Tab	1.00/1 Tab	Rupee One Only	L-2
165	Healer's Lab	2568	Aceclofenac 100mg + Paracetamol 325mg+ Serratiopeptidase 15mg Tab/Cap	1 Tab/Cap	ACEMARC SP	10 Tab	1.16/1 Tab	Rupee One Paise Sixteen Only	L-3
165	Abbott Healthcare Pvt Ltd	1015a	Prochlorperazine Tab/Cap- Each Tab/Cap to contain: Prochlorperazine Maleate 5 mg	1 Tab/Cap	Stemetil MD	15 Tab	0.60/1 Tab	Paise Sixty Only	L-1

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	ALPA LABORATORIES LTD	1082a	Tramadol Inj-Each ml to contain: Tramadol Hydrochloride 50mg, 1ml Amp	1 Amp	Same as in Item	1ml Amp	3.52/1 Amp	Rupees Three Paise Fifty Two Only	L-1
165	Ipca Laboratories Ltd.	1375a	Leflunomide 10mg Tab/Cap-Each Tab/Cap to contain: Leflunomide 10mg	1 Tab/Cap	Lefno-10	10 Tab	1.49/1 Tab	Rupee One Paise Forty Nine Only	L-1
165	Torrent Pharmaceuticals Ltd.	1375a	Leflunomide Tab/Cap- Each Tab/Cap to contain: Leflunomide 10mg	1 Tab/Cap	LEFRA-10	10 Tab	1.76/1 Tab	Rupee One Paise Seventy Six Only	L-2
165	Torrent Pharmaceuticals Ltd.	1497a	Esomeprazole Tab/Cap-Each Plain/Gastro Resistant Tab/Cap To contain: Esomeprazole Magnesium 20 mg	1 Tab/Cap	NEXPRO-20	15 Tab	0.80/1 Tab	Paise Eighty Only	L-1
165	MEDOPHARM	1497a	Esomeprazole Tab/Cap-Each Plain/Gastro Resistant Tab/Cap To contain: Esomeprazole Magnesium 20mg	1 Tab/Cap	Esopel 20	10 Tab	0.84/1 Tab	Paise Eighty Four Only	L-2
165	UNICURE INDIA LTD	1497a	Esomeprazole Tab/Cap-Each Plain/Gastro Resistant Tab/Cap To contain: Esomeprazole Magnesium 20mg	1 Tab/Cap	Same as in Item	10 Tab	0.88/1 Tab	Paise Eighty Eight Only	L-3
165	PRECISE CHEMIPHARMA PVT LTD	1497b	Esomeprazole Tab/Cap - Each Plain/Gastro Resistant Tab/Cap to contain: Esomeprazole Magnesium 40mg	1 Tab/Cap	PRE-ESO 40	10 Tab	0.75/1 Tab	Paise Seventy Five Only	L-1
165	Healer's Lab	1497b	Esomeprazole Tab/Cap-Each Plain/Gastro Resistant Tab/Cap to contain: Esomeprazole Magnesium 40 mg	1 Tab/Cap	ESOMARC-40	10 Tab	1.25/1 Tab	Rupee One Paise Twenty Five Only	L-2
165	HAB Pharmaceuticals & Research Ltd	1497b	Esomeprazole Tab/Cap - Each Plain/Gastro Resistant Tab/Cap to contain: Esomeprazole Magnesium 40mg	1 Tab/Cap	ES-PROZOLE	10 Tab	1.28/1 Tab	Rupee One Paise Twenty Eight Only	L-3
165	ALPA LABORATORIES LTD	15b	Hyoscine Butyl Bromide Inj- Each ml to contain: Hyoscine Butyl Bromide 20mg., 1ml Amp	1 Amp	Same as in Item	1ml Amp	9.24/1 Amp.	Rupees Nine Paise Twenty Four Only	L-1

DG-ESIC Central Rate Contract No.165 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
165	Morepen Laboratories Limited	567b	Rabeprazole Tab/Cap - Each Plain/Gastro Resistant Tab/Cap to contain: Rabeprazole 20 mg.	1 Tab/Cap	Rabidoc-20	10 Tab	0.49/1 Tab	Paise Forty Nine Only	L-1
165	Wings Biotech LLP	567b	Rabeprazole Tab/Cap - Each Plain/Gastro Resistant Tab/Cap to contain: Rabeprazole 20 mg	1 Tab/Cap	same as in Item	10 Tab	0.50/1 Tab	Paise Fifty Only	L-2
165	Heal (India) Laboratories Pvt. Ltd.	567b	Rabeprazole Tab/Cap-Each Plain/Gastro Resistant Tab/Cap to contain: Rabeprazole 20 mg.	1 Tab/Cap	RABIRAZ-20	10 Tab	0.56/1 Tab	Paise Fifty Six Only	L-3

END OF RATE CONTRACT

क.रा.बी.नि.
ESIC